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1The research work incorporated in the thesis with the title “STUDIES ON
HETEROCYCLIC ENTITIES OF MEDICINAL INTEREST” has been  described
as under.
[A] STUDIES ON IMIDAZO[1,2-a]PYRIDINES
[B] STUDIES ON DIHYDROPYRIMIDINES
[A] STUDIES ON IMIDAZO[1,2-a]PYRIDINES
Heterocyclic compounds bearing imidazo[1,2-a]pyridine ring system are endowed
with variety of biological activities. Our strategy is based on to develop a new bioactive
entities especially with pharmacological activities bearing heterocyclic ring system.
Literature survey reveals that nitrogen containing heterocyclic compounds like
imidazo[1,2-a]pyridines have received considerable attention in medicinal science due
to their biological and pharmacological activities like anti-inflammatory, herbicidal,
hypnotic, sedative, antimicrobial, antitubercular, CNS depressant, antithyroid and many
other therapeutic activities.
These valid observations prompted us to design and synthesize some
heterocycles like chalcones, pyrazolines, cyanopyridines,mannich bases, pyrimidines,
isoxazoles, imidazolinones etc., bearing imidazo[1,2-a]pyridine nucleus,which have been
described as under.
PART-I  : STUDIES ON PYRAZOLINES
Among a wide variety of heterocycles that have been explored for developing
biologically active molecules like pyrazolines have played important role in medicinal
chemistry. Pyrazolines have been found to posses bactericidal, fungicidal, antiviral and
other  pharmacological  propert ies  l ike ant iconvulsant ,ant idepressant  and
anti-inflammatory. These valid observations led us to synthesize some new pyrazoline
derivatives for better drug potential which have been described in following sections.
2SECTION-I  : Synthesis and biological screening of (2E)-3-[2-(2,4-dichloro
  phenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones
The chalcones of Type(I) have been synthesized by the condensation of 2-(2,4-
dichlorophenyl)imidazo[1,2-a]pyridin-3-carbaldehyde with different aryl ketones in the
presence of 40 % NaOH.
SECTION-II  : Synthesis and biological screening of 3-(1-acetyl-3-aryl-4,5-
    dihydro-1H-pyrazol-5-yl)-2-(2,4-dichlorophenyl)imidazo[1,2-a]















Type-(I)    R = Aryl
Type- (II)    R = Aryl
Pyrazol ine  der iva t ives  of  Type(I I )  have  been synthes ized  by  the
cyclocondensation of the chalcones of Type (I) with hydrazine hydrate in glacial acetic
acid.
3PART-II  : STUDIES ON CYNOPYRIDINES
Like other heterocyclic compounds, pyridines with different functional groups
exhibit wide range of applications in the field of pharmaceutical and agriculture.
Cyanopyridine derivatives have been reported to be active as antifungal, antidiabetic,
anticholestemic and antihypertensive. On the basis of these results, we have synthesized
some new dervatives which have been described as under.
SECTION-I  : Synthesis and biological screening of 4-[2-(2,4-dichlorophenyl)
  imidazo[1,2-a]pyridin-3-yl]-2-methoxy-6-arylnicotinonitriles
Cyanopyridines of Type (III) have been synthesized by the condensation of the
chalcones of Type (I) with malononitrile and sodium methoxide.
PART-III  : STUDIES ON PYRIMIDINES
Pyrimidine nucleus possess remarkable pharmaceutical importance and
biological activities, some of their derivatives occur as natural products, like nucleic
acids and vitamin B. Many pyrimidine derivatives have displayed diverse
pharmacological activities like antitumor etc. In view of our on going interest in the
synthesis of substituted pyrimidines, the synthesis of some new potentially bioactive










Type-(III)    R = Aryl
4 SECTION-I  : Synthesis and biological screening of 6-[2-(2,4-dichlorophenyl)
   imidazo[1,2-a]pyridin-3-yl]-4-arylpyrimidin-2(1H)-ones
Pyrimidine derivatives of Type (IV) have been prepared by the cyclization of
chalcones of Type (I) with urea in presence of basic catalyst like KOH.
SECTION-II : Synthesis and biological screening of 6-[2-(2,4-dichlorophenyl)









Pyrimidinethione derivatives of Type (V) have been prepared by the
cyclocondensation of chalcones of Type (I) with thiourea in presence of basic catalyst
like KOH.

















Type - (VI)     R1, R2 = Aryl
PART-IV  :  STUDIES ON MANNICH BASES
Mannich base containing bridge N-atom exhibit diverse pharmacological
activities like antibacterial, antimalarial, antineoplastic, analgesic and anticonvulsant.
Mannich bases are also found as intermedate in organic synthesis and good chelating
agents. Hence it is pertinent to synthesize some new mannich bases, which have been
described as under.
SECTION-I  :Synthesis and biological screening of N-{[2-(2,4-dichlorophenyl)
  imidazo[1,2-a]pyridin-3-yl]methyl}-N,N-diaryl/alkyl amines
Mannich bases of Type (VI) have been synthesized by the condensation of 2-
(2,4-dichlorophenyl)imidazo[1,2-a]pyridine with different secondary amines and
formaldehyde in the presence of acidic catalyst like HCl.
PART-V  : STUDIES ON ISOXAZOLES
Isoxazole derivatives represent one of the modest class of compound possessing
broad range of biological activities such as antidepressants, skeleton muscle relaxant,
antidiabetic,anti-inflammatory, analgesic etc. In order to developing medicinally
important compounds we have synthesized some isoxazole derivatives shown as under.









Type - (VII)     R = Aryl
Isoxazole derivatives of Type (VII) have been prepared by the reaction of
chalcones of Type (I) with hydroxylamine hydrochloride in the presence of sodium
acetate in acetic acid.
PART-VI  : STUDIES ON ARYLAMINOMETHYL DERIVATIVES
Arylaminomethyl derivatives represents one of the modest class of biological
active agents which have been deeply studies during search on new potential agents.
These have been reported to be active as antimicrobial, antitubercular, anticancer,
insecticidal etc. In view of these valid observations, it was contemplated to synthesis
some new arylaminomethyl derivatives possessing higher biological activity which have
been described as under.








Type - (VIII)  R = Aryl
7The azomethines of Type (VIII) have been prepared by the condensation of 2-
(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-carbaldehyde with different aromatic
amines.
SECTION-II :Synthesis and biological screening of N-{[2-(2,4-dichloro
  phenyl)imidazo[1,2-a]pyridin-3-yl]methyl}-N-arylamines
The compound of Type (IX) have been synthesized by the reaction of arylamines
of Type (VIII) with an. NaBH4.
PART-VII  : STUDIES ON IMIDAZOLINONES
The group of compounds containing the imidazolinone ring system have a
prominent feature in medicinal chemistry. 5-Oxoimidazoline derivatives have been
reported to be active as anticonvulsant, potent CNS depressant, anticancer, sedative,
hypnotics and as mono amino oxidase (MAO) inhibitor. In view of the above finding
some new imidazolinone derivatives bearing imidazo[1,2-a]pyridine nucleus, which have
been described as under.









Type - (IX)  R = Aryl
8The imidazolinone derivatives of Type (X) have been synthesized by the reaction
of azalactone with different arylamine in pyridine.
[B]  STUDIES ON DIHYDROPYRIMIDINES
The synthesis of dihydropyrimidine derivatives is important drug potential  because of their
pharmacological activities such as antiviral, antitumor, antibacterial and anti-inflammatory. Many of
them are biologically important since they behave as calcium channel blockers, antihypertensive
agents. This observation led us to synthesise of some newer dihydropyrimidinones and
dihydropyrimidinethiones derivatives shown as under.
PART-I  :   STUDIES ON DIHYDROPYRIMIDINONES
Dihydropyrimidinone and its derivatives have been important task for the research
chemist as they possess biological activities such as significant in vitro activity against
unrelated DNA and RNA virus, antimalarial, diuretic, antimicrobial, antileukemic and
antineoplastic. The above observations created the interest for the synthesis of the
series of dihydropyrimidinones which have been described as under.


















Type - (XI)  R = Aryl
9Dihydropyrimidinones of Type (XII) have been synthesized by the
cyclocondensation of 4-methyl--N-(4-methylphenyl)-3-oxo-pentanamide, urea and aryl
aldehydes.
PART-II  :   STUDIES ON DIHYDROPYRIMIDINTHIONES
Dihydropyrimidinthione and its derivatives represents one of the most active class
of compounds possessing a broad spectrum of pharmacologically activities like
anti-inflammatory, antibacterial, calcium channel blockers, antihypertensive agent and
anticancer. In view of these facts, we have undertaken the synthesis of compounds as
shown as under.











Type - (XII)  R = Aryl
Dihydropyrimidinones of Type (XI) have been synthesized by the condensation
of 4-methyl-3-oxo-N-phenylpentanamide, urea and aryl aldehydes.
SECTION-II : Synthesis and biological screening of 6-isopropyl-4-aryl-N-
   (4-methylphenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-
   carboxamides
10
Dihydropyrimidinthiones of Type (XIII) have been synthesized by the cyclization of 4-
methyl--N-(4-methoxyphenyl)-3-oxo-pentanamide with thiourea and aryl aldehydes.





















Type - (XIV)  R = Aryl
Dihydropyrimidinthiones of Type (XIV) have been prepared by the
condensation of 4-methyl--N-(4-fluorophenyl)-3-oxo-pentanamide, thiourea and aryl
aldehydes.
The constitution of the synthesised compounds have been characterised using
elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity off all the copounds have been checked
by thin layer chromatography.
11
 In vitro studies on multiple biological activities.
 (I) Selected compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv
at a concentration of 6.25 µg/ml using Rifampin as  s tandard  drug,  which
have been tested by Tuberculosis  Antimicrobial Acquisition Co-ordinating
Facility (TAACF), Alabama, U.S.A.
 (II) All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal
activity towards Aspergillus niger at a concentration of 40 mg/ml. The
biological activity of the synthesized compounds have been compared with
standard drugs.
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INTRODUCTION
With the advancement in science and technology, remarkable progress has been
made in the field of medicine including diagnosis, treatments and pharmaceutics. Recent
drug discovery techniques based on Structure Activity Relationships, High Throughput
Screening and Spectroscopy have triggered and spearheaded the discoveries of many
natural and synthetic drugs.
Despite these developments, of the known 30,000 Human diseases or disorders,
only one third can be treated symptomatically with drugs (either in part or fully) and that
to a great economic and social cost. This is because of the fact that the drug available
today are still not very effeetive perticularly with respect to the fight against drug
resistant pathogens and newly emerging infections. This include infectious diseases such
as AIDS, influenza, tuberculosis and malaria as well as other chronic disorders like
cancer, central nervous system disabilities ( e. g. Alzheimer’s disease). These infectious
diseases (microbial) will continue to be the leading causes of permature death in human
beings of both developed and developing nations as their resistance to many
conventional drugs is increasing. Therefore, microbial resistance especially by bacteria
and protozoa to drugs is of special concern to communities worldwide and to
researchers.
The discovery of bacteria in 1683 by van Leuwenhoek helped mankind to
understand the infectious pathogens and appropriately develop antiseptic and antibiotic
protocol in the following years. By the beginnning of 20th century, Paul Ehrlich proposed
the principle of chemotherapy and his work including Structure Activity Relationships
significantly contributed to shaping synthetic protocols and helped in the later
discoveries of antibacterial drugs. Antibiotics were designed either to kill bacteria
(bactericidal) or to nullify growth (bacteriostatic) and three groups of antibacterial agents,
which included bacterial cell wall inhibitors, protein synthesis inhibitors and DNA
inhibitors, were developed to fight the bacterial infections. The sulphonamides were the
Studies on heterocyclic....
        Introduction....
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first group of effective antibacterials to be developed following a chance discovery in
1932 by Domagk of antibacterial activity in the synthetic azo dye, prontosil.
In 1928, Alexander Fleming observed that colonies of Staphylococcus bacteria
were dissolved by penicillium mould. This discovery was then further developed by Florey
and Chain when in 1939 they demonstrated that the active component from the mould,
penicillin, could cure a human bacterial infection. This key finding lead to the
industrialisation of the production of penicillin as an antibiotic in 1943. Four years later
the first penicillin resistant bacteria were observed.
Many antibacterial drugs were developed in the late 1940s following the first
report of resistance in Staphylococcus aureus (1941) and in Mycobacterium
tuberculosis (1940s), a mycobacterium which also developed resistance later to the
drugs isoniazid and rifamycin in the 1950s and 1960s. However, by the 1980s most
major infectious diseases in the developed world were almost eradicated and half the
major pharmaceutical companies in Japan and the USA stopped their antibacterial drug
development programs. As a result drug resistant pathogens were on the rise
worldwide. Streptococci that causes nosocomial infections showed innate resistance to
drugs including cephalosporins, clindamycin and aminoglycoside. The bacterium
(Staphylococcus aureus) has now developed multi drug resistant strains and threatens
to put an end to successful chemotherapy.
Bioactive natural products are mainly secondary metabolites which are used by
the host as defensive and protective mechanisms against their enemies and predators.
Generally, screening of these secondary metabolites and development of drugs is a very
hard task requiring much effort starting from botanical identification, collection,
extraction, isolation, purification and compound identification to pharmacological and
clinical testing. However, the enormous chemical diversity and highly unusual structures
provided by natural products is greater than that provided by most available
combinatorial approaches based on heterocyclic compounds.
Studies on heterocyclic....
        Introduction....
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Today the chief source of agents for the cure, the mitigation or prevention of
disease are organic, natural or synthetic, together with so called organometallics. Such
agents have their origin in a number of ways (a) From naturally occuring materials of
both plant and animal origin and (b) From the isolation of organic compounds
synthesized in laboratory whose structures are closely related to those of naturally
occuring compounds for e.g. atropine, steroids, morphine, cocaine etc.
Heterocyclic compounds are used as pharmaceuticals, as agrochemicals and as
vaterinary products. They are used as optical brightening agnets, as antioxidants, as
corrosion inhibitors, and as additives with a variety of other functions. Heterocyclic
comopounds are also finding an increasing use as intermediates in organic synthesis.
AIMS AND OBJECTIVES:
In the  pharmaceutical field, these had always been and will continue to be need
for new and novel chemical inhibitors of biological function. Our efforts are focused on
biological function of chemical diversity in the molecular frame work in order to
synthesising pharmacologically interesting compounds of widely different composition.
During the course of research work, looking to the application of heterocyclic
compounds, several entities have been designed, generated and characterised using
spectral studies. The details are as under.
(I) To generate several derivatives like chalcones, pyrazolines, cyanopyridines,
pyrimidines, isoxazoles, mannich bases, arylaminomethyl derivatives,
imidazolinones bearing imidazo[1,2-a]pyridine moiety.
(II) To generate several derivatives like dihydropyrimidinones and
dihydropyrimidinthiones.
(III) To characterize these products for structure elucidation using spectroscopic
technique like IR, 1H NMR and Mass spectral studies.
(IV) Purity of all compounds have been checked by thin layer chromatography.
(V) To evaluate these new product for better drug potential against different
strain of bacteria, fungi and for antitubercular activity.
    [A]
STUDIES ON
IMIDAZO[1,2-a]PYRIDINES
Studies on heterocyclic.... 15
 Imidazo[1,2-a]pyridines...
INTRODUCTION
Bridge nitrogen containing fused heterocycles represents important building blocks
in both natural and synthetic bioactive compounds which have been shown to possess
diverse therapeutic activities1. Hence they are interesting target to be prepared to our
research on medicinally interesting heterocyclic entities. Aza-indolizine are of two types,
imidazo[1,2-a]pyridine (I) and imidazo[1,5-a]pyridine (II).
The aza-indolizine contains a phenyl ring fused to a imidazole ring is indicated in
the structure, hence it is also known as imidazo[1,2-a]pyridine2. Several procedure for
their synthesis have been extensively studied. Such studies have been stimulated by various






            ( I )                                                 ( II )
The constitution of imidazo[1,2-a]pyridine was represented by W. L. Mosby3.
Imidazo[1,2-a]pyridine derivatives not only known for their medicinal applications, but
they are also used in disperse dye4.
SYNTHETIC ASPECT
Several methods have been reported in the literature for the synthesis of
imidazo[1,2-a]pyridines. The procedure for synthesizing imidazo[1,2-a]pyridines have
been described as under.
1. The Tschitschibabine5 has synthesize imidazo[1,2-a]pyridine from 2-aminopyridine
with ω-bromoacetophenone.
Studies on heterocyclic.... 16
 Imidazo[1,2-a]pyridines...
2. Paudler et al.6 have synthesized 5-amino-3-formyl imidazo[1,2-a]pyridine
from acid catalyzed hydrolysis of 1,4-diazacycl[3,2,2]azine.
3. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination
of nitrogens give imidazo[1,2-a]pyridine7
4. Groziak et al.8 have synthesized imidazo[1,2-a]pyridine by the condensation
of 2-aminopyridine with glyoxal trimer dehydrate in aqueous NaHSO3.
5. Imidazo[1,2-a]pyridine9 nucleus can be also synthesized by the reaction of
α-ketohydrazidoyl halide with heterocyclic amines.
6. Tsai et al.10 have been prepared 3-amino imidazo[1,2-a]pyridine derivatives
by a three component condensation reaction between 2-aminopyridine,




























































































    The majority of  imidazo[1,2-a]pyridine have been synthesized by the reaction of
2-aminopyridine with a α-halocarbonyl compound which form oniumhalide (III) which
is further cyclize at room tempeture to gives imidazo[1,2-a]pyridine.
7. Shawali et al.11 have synthesized imidazo[1,2-a]pyridine nucleus by the
reaction of α-ketohydroximoylchloride with 2-aminopyridine.
Studies on heterocyclic.... 18
 Imidazo[1,2-a]pyridines...
THERAPEUTIC IMPORTANT
      Imidazo[1,2-a]pyridines are potential bioactive agents due to their wide spectrum
of therapeutic importance. A large number of substituted imidazo[1,2-a]pyridine
derivatives are prepared and tested for varieties of biological activities. some of them
are as under.
1.      Antiulcer12,13
2.      Long-acting local anesthetic14
3.      Antiviral15,16
4.      Hypnotic17
5.      Antianxiety18
6.      Antibacterials19,20
7.      Antifungal agents21
8.      Calcium channel blockers22
9.      Antiherpetic activity23,24
10.      Antiinflammatory, analgesic, antipyretic25,26
11.      Gastric antisecretory27,28
12.      Hypnoselective and anxioselective activities29
13.      β-Amyloid formation inhibitors30
14.      Active nonpeptide bradykinin B2 receptor antagonists
31
15.      Nonsedative anxiolytic32
16.      Benzodiazepine receptor agonists33
17.      Anticytomegalo-zoster and antivaricellazoster virus34-36
18.      Cardiotonic agents37
19.      Anthelmintic38
Several imidazo[1,2-a]pyridines already in market include alpidem39 [a ligand
of both the central benzodiazepine receptors and the peripheral type (Mitochondrial)
benzodiazepine receptor] has sedative and anxiolytic properties and zolpidem39
[a selective ligand for the central benzodiazepine receptor] is a hypnotic drug. Both
Studies on heterocyclic.... 19
 Imidazo[1,2-a]pyridines...
alpidem and zolpidem  have higher affinity for benzodiazepine-1 than for


















 Alpidem     Zolpidem
James J. Kaminski and co-workers42 have investegated the imidazo[1,2-a]pyridine
derivative 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine (III) as
an antiulcer agent. On the basis of the reported metabolism of zolimidine, they reported









               (III) Zolimidine
Alexander C. Humphries and co-workers43 have synthesized 8-fluoro
imidazo[1,2-a]pyridine derivatives (IV) and evaluated as a bioisosteric replacement for
imidazo[1,2-a]pyridine in an allosteric modulator ligand of the GABAA receptor. Kristian
S. Gudmundsson44 have reported the synthesis and antiviral activities of newer
Erythrofuranosyl imidazo[1,2-a]pyridine C-nucleosides. I. Aramori et al.45 have been
synthesized highly potent and selective non-peptide bradykinin receptor antagonist (V).























            (IV)
            (V)
The imidazo[1,2-a]pyridine units appear as important building blocks in both
natural and synthetic bioactive compounds.46-48 Mohamed A. Ismail49 have synthesized
some novel diamidine imidazo[1,2-a]pyridine like (VI) and (VII) and 5,6,7,8-tetrahydo
imidazo[1,2-a]pyridines and their corresponding N-hydroxy and N-methoxy analogues
which are potential for this series and their evaluation versus Trypanosoma b. rhodesiense
(T. B. rhodesiense) and plasmodium falciparum (P. falciparum). Aromatic diamidines
exhibit broad spectrum antimicrobial activity including effectiveness againts the
protozoan disease caused by Trypanosoma SP and Plasmodium SP50.










a - R: H








a - R: H;pera connection
b - R: H;meta connection
S. Kristjan, Gudmundsson, A. Brian Johns51 and A. Chaouni Bendallay et al.52
have worked on synthesis of a novel imidazo[1,2-a]pyridine shown in (VIII) with potent
activity against Herpes Simplex viruses.
        (VI)








      ( VIII )
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 Imidazo[1,2-a]pyridines...
Thus the important role displayed by imidazo[1,2-a]pyridine and its derivatives
for various therapeutic and biological activities prompted us to synthesize some Chalcones,
Acetyl pyrazolines, Cyano pyridines, Thiopyrimidines, Oxopyrimidines, Mannich bases,
Isoxazoles, Schiff bases, Imidazolinone derivatives bearing imidazo[1,2-a]pyridine moiety
in order to achive compounds having better biological activities as described in the
following parts.
STUDIES ON IMIDAZO[1,2-a]PYRIDINE DERIVATIVES
PART-I    : STUDIES ON PYRAZOLINES
PART-II  : STUDIES ON CYANOPYRIDINES
PART-III : STUDIES ON PYRIMIDINES
PART-IV : STUDIES ON MANNICH BASES
PART-V  : STUDIES ON ISOXAZOLES
PART-VI : STUDIES ON ARYLAMINO METHYL DERIVATIVES
PART-VII: STUDIES ON IMIDAZOLINONES
Studies on heterocyclic.... 23
 Imidazo[1,2-a]pyridines...
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The term “chalcone” was first coined by Kotanecki and Tambor1. The chemistry
of chalcones have generated intensive scientific studies throughout the world, specially
interesting for their biological and industrial applications. Chalcones are coloured
compounds because of the presence of the chromophore and auxochromes. They are
known as benzalacetophenones or benzylidene acetophenones. Chalcones (I) are
characterized by their possession of a structure in which two aromatic rings A and B are
linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl styryl ketones,
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene and α-
phenyl-β-benzoethylene.
SYNTHETIC ASPECT
A variety of a methods are available for the synthesis of chalcones. The most
convenient method is the one that involves the Claisen-Schmidt condensation of equimolar
quantities of a aryl methyl ketones with aryl aldehyde in the presence of alcoholic alkali.2-
3 Various condensing agent used for the synthesis of chalcones are alkali of different
strength.4,5, Hydrogen chloride6,7, Phosphorous oxychloride8, Piperidine9, Anhydrous
Aluminium Chloride10, Boron trifluoride11, Borax12, Aminoacids13, Perchloric acid14 etc.
MECHANISM







The  in te rmed ia te  aldo l  type  p roduc t s  fo rmed  read i ly  undergoes
dehydration even under mild condition, perticularly when R and R’are aryl groups.
REACTIVITY OF CHALCONES
The chalcones have been found to be useful for the synthesis of many heterocyclic
compounds.
1. Chalcones are intermediate compounds for the synthesis of some naturally
occuring heterocyclic compounds like flavones, flavanones, flavanoid,
dihydro flavanols, benzal coumarinones, anthocyanins, etc.
2. Chalcone contain a Keto-Ethylenic group and therefore reactive towards a
number of reagents yielding various heterocyclic compounds exhibiting
significant  biological  activit ies viz.  pyrazolines15,  cyanopyridines16,
cyanopyrans 17,  cyanopyridones 18,  pyr imidines 19-21,  i soxazoles 22,
indazoles23 etc.
3. They have been useful in providing structure of some natural products like
cyanomulcurin24, eviodictoyl25, hemlocktanin26, narighenin27, plioretin28 etc.
4. Chalcones are also useful for the detection of Fe(II)29 and Ca(II)30 ions in
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chalcones was used as an analytical reagent for amperometric estimation of
copper31 and for spectrophotomatric study of the germanium.32
5. Chalcone and their derivatives are also found to be applicable as light
stabilizing agent33, sweetening agent34, organic brightening agent, photo
sensitive material, polymerisation catalyst, scintillators as well as  fluorescent
whitening agent.
6. The chalcones are natural biocides35,36 and are well-known key intermidiate
in the synthesis of heterocyclic compounds possessing biodynamic behaviour.37-38
THERAPEUTIC IMPORTANCE
Chalcones derivatives have been found to possess wide range of therapeutic















Chalcones are potential biocides, because some naturally occurring antibiotics63
and aminochalcones64,65 probably own their biological activity in the presence of the





Prem P. Yadav and co-workers67 have synthesized nitrogen and sulfur containing
furanoflavonoids and thiophenylflavonoids (III), Which have been screened for antifungal
and antibacterial activity. Meng C. Q. et al.68 discovered some novel heteroaryl



















         (IV)
Some dihydrochalcones are well known for their sweetening property69,70 and
appear to be non-nutritive sweeteners. A dihydrochalcone Uvaretin from Uvaria




 V. K. Ahluwalia et al.72 have noted that 5-cinnamoylchalcones (V) have shown
good as antibacterial activity.
Paula Boeck et al.73 have synthesized novel chalcone analougs (VI) with
antileishmanial activity. Analougs containing nitro, fluorine or bromine group respectively
displayed increased selectivity against the parasites as compared with natural chalcone.
   (VI)
Furthermore, Alcaraz M. J. et al.74 have described the role of nuclear
factor-kappaB and heme oxygenase-1 in the mechanism of act ion of  an
antiinflammatory activity of chalcone derivative. Nerya O. et al.75 have prepared chalcones
as potent tyrosinase inhibitors. Sabzevari O. et al.76 have constructed some new chalcone
derivatives (VII) as molecular cytotoxic mechanisms for anticancer activity. Aneta




























Chalcones have been proved to be an important intermediate for the synthesis of
many heterocyclic compounds in organic chemistry. These facts pormpted us to sythesize










The chemistry of pyrazoline was reviewed by Jarobe in 1967. Pyrazoline has
three possible tautomeric structures, but the structure (I) shown is the most stable which
can be prepared by the action of hydrazine hydrate with acrolein.
2-Pyrazoline consist a unique class of five member nitrogen heterocycle. During
the past year considerable evidance has been accumulated to demostrate the importance
of 2-pyrazoline derivatives. There has been considerable interest in the pyrazoline ring
system both with regard to heterocyclic chemistry and the pharmacological activities of
several of its derivatives.
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives  documented in
literature are as follows.
1. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcones78
2. Epoxy ketone reacts with hydrazine and phenyl hydrazine to give pyrazolines79.
Furthermore, B. Gyassi et al.80 investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation S. Paul et al.81 and
Dandia Anshu et al.82 have alsodescribed the microwave assisted synthesis of
2-pyrazolines.
3. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazines.83
4. 2-Pyrazolines (II) can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate.84












The following mechanism seems to be operable for pyrazoline by the































Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system (I) forms species (II), in which the negative charge is mainly accomodated
by the electronegative oxygen attom.
Proton transfer from the nitrogen to negative oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular nucleophilic
attack by the primary amino group of ketoamine on its carbonyl carbon followed by
proton transfer from nitrogen to oxygen leads ultimately to carbonyl amine (IV). The
later with a hydroxy group and amino group on the same carbon lose water molecule to
















From the literature survey, it was revealed that 2-pyrazolines are better therapeutic
agents. They possess valuable bioactivities like
1. Antimicrobial86















Moreover F. Manna et al.106 have described 1-acetyl-5-(2'-bromophenyl)-4,5-
dihydro-3-(2'-hydroxyphenyl)-1H-pyrazoline and its derivatives act as potent
antiinflammatory, analgesic and antipyretic agents. Udupi R. H. and Bhatt A. R.107 have
reported the synthesis and biological activity of Mannich bases of certain 1,2-pyrazolines.
Nugent Richard108 investigated pyrazolines bis phosphonate ester as novel
antiinflammatory and antiarthritic agent. Fuche Rainer et al.109 have prepared some new
1H-pyrazoline derivatives (III) and reported them as  pesticides. Furthermore, Tsubai
et al.110 have synthesized some new(phenylcarbamoyl) pyrazolines (IV) as an insecticides




Abdalla M. M. et al.111 have synthesized pyrazolines and tested their
antiandrogenic activity. Berghot M. A. et al.112 have prepared pyrazolines as antibacterial
agents. Maurer Fritz et al.113 have synthesized pyrazoles and screened for their pesticidal
activity.
E. Palska et al.114 have prepared 3,5-diphenyl-2-pyrazolines (V) and cited their
antidepressant activity. B. Shivrama et al.115,116 have synthesized pyrazolines as
antibacterial agents. Hiremath S. P. et al.117 have reported pyrazolines as analgesics,
antiinflammatory and antimicrobial agents. Goodell et al.118 have synthesized some newer
1,3,5-trisubstituted pyrazoline derivatives (VI) which shows anti west nile virus activity.
Almstead J. et al.119 have prepared pyrazolines as vascularization agents. Guniz
Kuchkguzel et al.120 have synthesized pyrazolines as a antimicrobial and anticonvulsant
agents. Gulhan T. Z. and co-workers121 have prepared pyrazolines as a hypotensive
agent.

























Moreover, T. M. Stivensen et al.122 have also investigated N-substituted pyrazoline
type insecticides. Tanka Katsohori123 have patented pyrazoline derivatives as herbicides
and Johannes et al.124 as insecticides. Moritaz Z. and Hadol125  investigated a semi
emperial molecular orbital study on the reaction of aminopyrazolinyl azodye with singlet
molecular oxygen. Shivnanda M. K. and co-workers126 have prepared substituted
pyrazolines and reported their antibacterial activity.
S. S. Sonarc et al.127 have synthesized-3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted phenyl)-pyrazolines and tested their antimicrobial activity. H. H. Parekh128
et al. have also synthesized some new pyrazolines as an antimicrobial agent. G. N.
Mishirika et al.129 have also prepared 2-pyrazolines of salicyclic acid  possessing
antimicrobial properties. Tunfawy, Atif and co-workers130 have patented 3-methyl-4'-
(substituted phenylazo)-pyrazol-5-ones as antibacterial agents.
Thus, significant biological  properties associated with pyrazoline derivatives have
aroused considerable interest to design the compounds with better drug potential and to
study their pharmacological profile, which have been described as under.
SECTION-I  : SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)-
3 - [ 2 - ( 2 , 4 - D I C H L O R O P H E N Y L ) I M I D A Z O [ 1 , 2 -
a]PYRIDIN-3-YL]-1-ARYLPROP-2-EN-1-ONES







SYNTHESIS AND BIOLOGICAL SCREENING OF ( 2E ) - 3 - [ 2 - ( 2 , 4 -
DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-1-ARYLPROP-2-EN-
1-ONES
Chalcone derivatives occupy a unique place in the field of medicinal chemistry
due to wide range of biological activities exhibited by them, prompted by these facts,
the preparation of chalcones of Type (I) have been carried out by condensation of 2-
(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde  with different ketones.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The





















































Gram positive bacteria : Staphylococcus aureus
Bacillus Coccus
Gram negative bacteria : Pseudomonas aeruginosa
Aerogenes
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzyl Penicillin,
Ciprofloxacin, Erythromycin,
Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin, Benzyl
Penicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared with viz





Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency
range: 4000-400 cm-1 (KBr disc.)
Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2966 2975-2950 131
-CH3 C-H str. (sym.) 2864 2880-2860  ,,
C-H def. (asym.) 1462 1470-1435  ,,
C-H def. (sym.) 1375 1390-1370  ,,
Aromatic C-H  str. 3084 3090-3030 132
C=C str. 1493 1540-1480  ,,
Halide C-Cl str. 731 800-600 131
Vinyl CH=CH str. 3017 3050-3000  ,,
Chalcone C=C str. 1552 1580-1550  ,,
C=O str. 1665 1672-1652  ,,
Imidazo[1,2-a] C=N Str. 1597 1612-1593  ,,
pyridine C-N Str. 1168 1220-1020 132
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Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.5 3H    singlet     Ar-OCH3    -
2 6.92-6.95 2H     doublet     Ar-H(a,a')             J=9
3 7.10-7.02 1H     doublet     Ar-H(x)                J=15
4 7.30-7.50 4H    multiplet    Ar-H(g,h,i,j)     -
5 7.62 1H     doublet     Ar-H(e) J=2.1
6 7.70 1H      dd     Ar-H(c)          J=9.0,J=3.0
7 7.82 2H     doublet     Ar-H(b,b') J=9.0
8 7.95 1H     doublet    Ar-H(y) J=18.0




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz


























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)-3-[2-(2,4-
DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-1-ARYLPROP-2-EN-
1-ONES
(A) Synthesis of  2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridine
           To the solution of 2-amino pyridine (23.5 gm, 0.25 mol), 2-chloro-1-(2,4-
dichlorophenyl)ethanone (22.4 gm, 0.1 mol) in DMF (250 ml) was added. The reaction
mixture was stirred and reflux for 4 hour. After cooling, the crystallized product was
filtered  and dried in vacuum. Yield 72%, m.p172oC, Anal. Calcd. for C13H8CL2N2 :
Require: C, 59.34, H, 3.06, N, 10.65 % ; Found: C, 59.12, H, 3.02,  N, 10.67 %.
(B) Synthesis of 2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridine-3 carbaldehyde
To a well mixed solution of phosphorus oxychloride (11 ml ), chloroform (32 ml)
and DMF (8 ml) maintained at 0-10oC, was added slowly to a solution of 2-(2,4-
dichlorophenyl)imidazo[1,2-a]pyridine (5.26 gm, 0.02 mol) in 140 ml chloroform. The
mixture so obtined was refluxed for 8 hour. Cool the solution and evaporated to dry in
vaccum. The residue was treated with cold water, filter and crystallized from methanol.
Yield 90%, m. p. 212oC , Anal. Calcd. for C14 H8 Cl2 N2O Require : C, 57.76, H, 2.77,
N, 9.62 % ; Found: C, 57.70, H, 2.80, N, 9.60 %.
(C) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
(4-methoxyphenyl)prop-2-en-1-one
Dissolve  2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-3 carbaldehyde (2.91gm,
0.01mol)in a  mixture of  methanol  (25 ml)  + DMF (25 ml) .  To this  add
p-methoxyacetophenone (1.40gm, 0.01mol) and methanol (25 ml). Stirr the content at
room temperature for 24 hr. in presence of catalytical amount of 40% KOH. The resulting
solution was poured on to crushed ice, thus the solid seprated was filterated and
crystallized from ethanol, Yield 56 %, m. p. 180oC , Anal. Calcd. for C23H16Cl2N2O2
Require : C, 65.26, H, 3.81, N, 6.62 % ; Found: C, 65.24, H, 3.80, N, 6.60 %.





(D) Biological screening of  (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]-1-arylprop-2-en-1-ones
(a) Antibacterial activity
The purified products were screened for their antibacterial activity using cup-
plate agar diffusion method. The nutrient agar broth prepared by the usual method was
inoculated aseptically with 0.5 ml of 24 hr. old subcultures of Bacillus coccus,
Staphylococcus aureus, Aerogenes, Pseudomonas aeruginosa in separate conical
flasks at 40-500C and mixed well by gentle shaking. About25 ml content of the flask
was poured and evenly spreaded in a petridish (13 cm diameter) and allowed to set for
2 hr. The cups (10 mm diameter) were formed by the help of borer in agar medium and
filled with 0.04ml (40mg) solution of sample in DMF.The plates were incubated at 370C
for 24 hr. and the control was also maintained with 0.04ml of DMF in a similar manner
and the zone of inhibition of the bacterial growth were measured in millimeter and recorded
in Graphical Chart No. 1
(b) Antifungal activity
Aspergillus niger was employed for testing antifungal activity using cup-plate
agar diffusion method. The culture was maintained on sabourauds agar slants sterilized
sabourauds agar medium was inoculated with 72 hr. old 0.5ml suspension of fungal spores
in a separate flask. About 25 ml of the inoculated medium was evenly spreaded in a
petridish (13cm diameter) and allowed to set for 2 hr. the cups (10mm diameter) were
punched. The plates were incubated at 30 0C for 48 hr. After the completion of incubation
period, the zone of inhibition of growth in the form of diameter in mm was measure.
Along the test solution in each petridish one cup was filled up with solvent, which acts as
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SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(1-ACETYL-3-ARYL-4,5-
DIHYDRO-1H-PYRAZOL-5-YL)-2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINES
The broad spectrums of pharmacological properties have been demonstrated by
the pyrazoline nucleus. Inspired by these facts, new pyrazoline derivatives of Type (II)
have been investigated. The (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones of Type (I) on treatment with hydrazine hydrate in acetic acid yielded
3-(1-acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-2-(2,4-dichlorophenyl)imidazo[1,2-
a]pyridines derivatives of Type (II).
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The





















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2962 2975-2950 131
-CH3 C-H str. (sym.) 2864 2880-2860   ,,
C-H def. (asym.) 1460 1470-1435   ,,
C-H def. (sym.) 1382 1390-1370   ,,
Aromatic C-H  str. 3056 3090-3030 132
C=C str. 1517 1540-1480   ,,
Ether C-O-C str. 1256 1260-1200   ,,
Pyrazoline C=O str. 1661 1612-1593 131
C=N str. 1605 1612-1593   ,,
N-H str. 3374 3400-3200   ,,
Imidazo[1,2-a] C=N str. 1595 1612-1593   ,,
pyridine C-N str. 1032 1220-1020             ,,
Halide C-Cl str. 784 800-600 132
IR SPECTRAL STUDIES OF 3-(1-ACETYL-3-(4-METHOXYPHENYL)-4,5-
DIHYDRO-1H-PYRAZOL-5-YL)-2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency

















































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz



























1     2.26     3H        singlet      Ar-CO-CH3    -
2     3.25     1H        dd      C-H(a)                  -
3     3.68     1H        dd      C-H(b)                  -
4     3.85     3H        singlet      Ar-OCH3    -
5     5.81     1H        dd      C-Hc                  -
6     6.80     1H        doublet      Ar-H(l) J=6.2
7     6.91     2H        doublet      Ar-H(e,e') J=9.0
8     7.15-7.40     4H        multiplet     Ar-H(g,h,i,j)     -
9     7.57     1H        dd      Ar-H(k)          J=9.0,J=2.1
10     7.63     2H        doublet      Ar-H(d,d') J=9.0


























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 3-(1-ACETYL-3-ARYL-4,5-
DIHYDRO-1H-PYRAZOL-5-YL)-2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDINES
(A) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
arylprop-2-en-1-ones
See (A)Part-I, Section-I (C).
(B) Synthesis of 3-(1-Acetyl-3-(4-methoxphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-
2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine
A mixture of (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
(4-methoxyphenyl)prop-2-en-1-one (4.23 gm, 0.01 mol) and hydrazine hydrate (0.5gm,
0.01 mol) in glacial acetic acid (25 ml) was refluxed for 8 hr. The product was  isolated
and crystallized from ethanol. Yield 64 %, m.p. 200 oC, Anal. Calcd. for C25H20Cl2N4O2;
Requires: C, 62.64; H, 4.21; N, 11.69 %; Found: C, 62.63; H, 4.20; N, 11.68 %.
Similarly, other 3-(1-acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-2-(2,4-
dichlorophenyl)imidazo[1,2-a]pyridines were prepared. The physical data are recorded
in Table No.2
(C) Biological screening of 3-(1-Acetyl-3-aryl-4,5-dihydro-1H-pyrazol-5-yl)-2-
(2,4-dichlorophenyl)imidazo[1,2-a]pyridines
Antimicrobial testing were carried out as described in (A) Part-I Section-I(D).
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Pyridine with different functional groups, exhibit wide range of applications in
the field of medicine, agriculture and dyes. Although many substituted pyridine compounds
like other heterocyclic compounds are synthesized with their functional group present
from a cyclic compounds. The simple pyridine compounds are prepared by the cyclization
of aliphatic raw material. The availability of 3-cyanopyridines, nicotinamide and nicotinic
acid make possible their use as synthetic intermediates.
Most of pyridine derivatives are synthesized by manipulation of pyridine and its
simple homologues in a manner similar to chemistry of the benzenoid chemistry. However
the simple pyridine compounds are prepared by the cyclization of aliphatic raw materials.
In our continuation work in the chemistry of pyridine nucleus, we have undrtaken the




Different methods for the preparation of 3-cyanopyridines are available in
literature.1-7 The well known methods are:
1. Substituted cyanopyridine derivatives were prepared from 3-substituted phenyl
pyrazolone derivatives with malononitrile.8
2. Samour and co-workers9 have prepared substituted cyanopyridines by
the condensation of chalcones with malononitrile in presence of ammonium
acetate.
3. Sakurai and Midorikaw10,11 have reported that malononitrile reacts with
α,β-unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines.
4. Matthew D. Bowman et al.12 have synthesized fluorescent cyanopyridine































































The reaction proceeds through conjugate addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridines have attracted considerable attention as they appeared of interest
to possess antibacterial, anticholestemic, antifungal, antihypertensive and antidiabetic
activities. E. G. Hammana Abou and co-workers13 have studied anticancer and anti HIV
activity of 3-cyanopyridines. Abdallah Navine et al.14 have prepared cyanopyridine
derivatives which showed analgesic and antiinflammatory activity. Manna Fedele and
co-workers15 have reported the antiinflammatory activity of  3-cyanopyridines. H. Yoshida




derivatives. Abd El-Galil and co-workers17 have prepared 3-cyanopyridines (I) and
studied their pharmacological activity. Gadaginamath et al.18 have synthesized various
cyanopyridyl derivatives (II) and documented their variety of biological activities.
Many naturally occurring and synthetic compounds containing the pyridine scaffold
possess interesting pharmacological properties19. Among them, 2-amino-3-
cyanopyridines have been identified as IKK-2 inhibitors20.
J. J. Baldwin21-23 have prepared cyanopyridines exhibiting antihypertensive activity.
Streightoff24 and Seydal25 have studied the bacteriostatic effect of some  substituted 3-
cyanopyridines. Francis and co-workers26 have studied the effect of some substituted
pyridines on the growth of the walker carcinosarcome-256 in tissue culture. Barton et
al.27 have reported fungicidal and insecticidal properties. John A. Tucker et al.28 have































W. Von Behenburg et al.29 have synthesized 2-amino-3,6-disubstituted pyridines
as antiepileptic agents. V.Scott and E. Joseph30,31 have prepared 2-amino-3-
cyanopyridine derivatives which were found to be useful as antipsoriasis  pharmaceuticals.
J. A. Vann Allan et al.32 have prepared fused heterocyclic 3-cyanopyridine (IV). Abu
and co-workers33 have prepared novel fused cyanopyridines (V) for the treatment and














Abdel Galil E. Amr et al.34 have synthesized heterocyclic  pyridine derivatives
(VI) fused with steroidal structure. Initially the acute toxicity of the compounds was
assayed via the determination of their LD50. Heterocyclic pyridine fused with steroid
structure are active as antiinflammatory agents. Henryk foks et al.35 investigated new 3-










Marco J. L. et al.36 have synthesized acetylcholinesterase inhibitors. Moustafa
M. A. et al.37 have prepared antibacterial agents. Eduardo H. S. Sousa et al.38
documented thionicotinamide coordinated to the a model system for the in vitro
activation of thioamides antituberculosis drugs. Rosentreter Ulrich et al.39 have
synthesized a new cyanopyridine as receptor agonists in the treatment of cardiac or




and co-workers40 have synthesized of o-trifluoromethylbiphenyl substituted
2-amino-nicotinonitriles (VIII) as inhibitors of farnesyl transferase.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a valuable
therapy for diabetes. Edwin B. Villhauer and co-workers41 have reported the first use of
solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution
phase synthesis that is practical up to the multikilogram scale. One compound, NVP-
DPP728 (IX), is profiled as a potent, selective and shortacting DPP-IV inhibitor that
has excellent oral bioavailability and potent antihyperglycemic activity.
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher biological
activity with least side effect have been described as under.































SYNTHESIS AND BIOLOGICAL SCREENING OF 4-[2-(2,4-DICHLORO
P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] - 2 - M E T H O X Y- 6 - A RY L
NICOTINONITRILES
Cyanopyridines play a vital role owing to their range of biological and
physiological activites. In the light of these biological activities and variety of industrial
applications, some new  4-[2-(2,4-dichlorophenyl)imidazo[1,2-a] pyridin-3-yl]-2-
methoxy-6-arylnicotinonitriles derivatives of Type (III) have been prepared, by the
cyclocondensation of (2E)-3-[2-(2,4-dichlorophenyl) imidazo[1,2-a]pyridin-3-yl]-
1-arylprop-2-en-1-ones of Type (I) with malononitrile in presence of sodium methoxide.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The
biological activities of synthesized compounds were compared with standard drugs.




















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2958 2975-2950 42
-CH3 C-H str. (sym.) 2870 2880-2860  ,,
C-H def. (asym.) 1456 1470-1435  ,,
C-H def. (sym.) 1380 1390-1370 ,,
Aromatic C-H  str. 3073 3090-3030 43
C=C str. 1534 1540-1480  ,,
Halide C-Cl str. 729 800-600 42
Ether C-O-C str. 1222 1260-1200 ,,
Pyridine C=C str. 1499 1650-1520 43
C=N str. 1605 1580-1550 ,,
Nitrile C=N str. 2338 2240-2120 ,,
Imidazo[1,2-a] C=N str. 1556 1580-1550 42
pyridine C-N str. 1040 1220-1020 ,,
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1(KBr disc.)
    IR SPECTRAL STUDIES OF 4-[2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-a]






















































Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1     3.86     3H        singlet      Ar-OCH3(a)      -
2     4.04     3H        singlet      Ar-OCH3(b)      -
3     6.59     1H        singlet      Ar-H(c)      -
4     6.87-6.98     4H        multiplet    Ar-H(g,h,i,j)      -
5     7.33-7.26     1H        dd     Ar-H(e)         J=6.0,J=1.5
6     7.43-7.33     1H        doublet      Ar-H(d) J=2.7
7     7.74-7.71     2H        doublet       Ar-H(k,k') J=9.0
8     7.90-7.84     2H        doublet      Ar-H(l,l' ) J=9.0




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz










































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 4-[2-(2,4-DICHLORO
P H E N Y L ) I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] - 2 - M E T H O X Y- 6 - A RY L
NICOTINONITRILES
(A) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-1-arylprop-2-en-1-ones
See (A) Part-I, Section-I (C).
(B) Synthesis of 4-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-
methoxy-6-(4-methoxyphenyl)nicotinonitrile
To a solution of (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-
1-(4-methoxyphenyl)prop-2-en-1-one(4.23 gm, 0.01 mol), malononitrile (0.60gm, 0.01
mol)  in methanol (10ml) and sodium methoxide, which prepared from sodium metal
(46mg) and absolute methanol (20ml) was added. The content was heated under reflux
with stirring for 12 hr. The reaction mixture was cooled and poured on to crushed ice,
the seperated solid was filtered out and crystallized from ethanol. Yield 62%, m.p. 175oC,
Anal. Calcd. for C27H18Cl2N4O2; Requires: C,64.68; H, 3.62; N, 11.17; Found: C, 64.66
; H, 3.60; N,11.16%.
      Similarly, other 4-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-2-methoxy-
6-arylnicotinonitriles were prepared. The physical data are recorded in Table No.3
(C) Biological screening of 4-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]-2-methoxy-6-arylnicotinonitriles
Antimicrobial testing were carried out as described in (A) Part-I Section-1 (D).
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Pyrimidine derivatives like uracil (I), thymine (II) and cytosine (III) occur widely
in nature showing remarkable pharmaceutical importance because of their diverse
pharmacological activities. Several analogues of nucleic acid have been used  as a
compound that interfere with the synthesis and function of nucleic acids, an example is
fluorouracil which has been used in cancer treatment.
Pyrimidine is considered to be a resonance hybrid of the charged and uncharged
cannonical structures, its resonance energy has been found to be less than benzene or
pyridine. The naturally occuring pyrimidine derivatives was first isolated by Gabrial and
Colman in 1870, and its structure was confirmed in 1953 as 5-β-D-gluco-pyranoside of
divicine.
SYNTHETIC ASPECT
A very important general method for preparing pyrimidines is the condensation
between a three carbon compounds of the type YCH2Z, where Y and Z = COR, CO2R,
CN, and compounds having the amidine structure R(C=NH)NH2, where R = OH (urea),
SH or SR (thiourea or its s-derivative). The condensation is carried out in the presence
of sodium hydroxide or sodium ethoxide. This general reaction may be illustrate by the





































The reaction of chalcone with guanidine hydrochloride in presence of
potassium t-butoxide in t-butanol yielded corresponding 2-amino pyrimidine derivatives.1
Pratibha Sharma and co-workers2 have investigated 4,6-dimethyl-5-[2-(2-methylprop-
1-enyl)-1H-benzimidazol-1-yl]pyrimidine-2(5H)-thiones (IV) under kinetically controlled
phase transfer catalysis conditions.
The condensation of the azaenolates derived from readily available ketimines
with fluorinated nitriles offers an efficient and straightforward entry to new
fluorinated 1,3-vinylogous amides. These versatile compounds in turn react with
























Fikret karci et al.4 have synthesized 4-amino-1H-benzo[4,5]imidazo[1,2-a]
pyrimidin-2-one by the reaction of 2-aminobenzimidazole with ethylcyanoacetate.
Pyrimidines (VI) can also be prepared by cycloaddition reaction of 1,3,5-triazines,which
act as electron deficient dienes.
N
N




















































R2 = SH, OH
        (VII)
There are many other methods of pyrimidine ring synthesis which are of more
limited scope. The reaction of 1,3-dicarbonyl compound or an equivalent  reagent with
formamide provides a route of several pyrimidine which are unsubstituted at the 2-posi-
tion.
REACTION MECHANISM






It is revealed from the literature survey that pyrimidine derivatives have been











Patil L. R. et al.15 have synthesized some new pyrimidines bearing paracetamol
and imidazolyl moieties. B. J. Ghiya et al.16 synthesized some mercapto pyrimidine
derivatives (VIII) and screened for their anticancer, antitubercular and anti HIV
activities.Kaplina N. V. and co-workers17have shown herpes inhibiting activity of some
mercapto pyrimidine derivatives (IX).
Paolo La Colla et al.18 have synthesized various 5-alkyl-2-(alkyl/cycloalkkyl thio)-
6-(2,6-dichloro/2,6-difluoro phenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones (X) and



















Marie Gompel and co-workers19 showed that pyrimidine derivatives (XI) inhibit
various protein kinases such as cyclin-dependent kinases, glycogen synthase kinase-3,
cyclic nucleotide-dependent kinases and casein kinase. Alistair H et al.20 have synthesized
a novel series of aminopyrimidine IKK-2 inhibitors which shows excellent in vitro
inhibition of this enzyme and good selectivity over the IKK1 isoform. The relative potency






























R1 = H, Me     R 2-4 = Cl,  F, NO2
R5 = H, Cl, F R6 = alkyl/cycloalkyl (X)
H. S. Joshi et al.21 have sythesized some new pyrimidines (XIV) as









Michael D. Varney and co-workers22 have synthesized and evaluated 5-thia-
2,6-diamino-4 (3H)-oxopyrimidines (XIII) as potent inhibitors of Glycinamide
Ribonucleotide Transformylase with potent cell growth inhibition.
(XIII)
Moreover, Chaudhari Bipinchandra et al.23 prepared N6-(2-aminopyrimidin-4-
yl)-quinoline-4,6-diamine as N-type calcium channel antagonists for the treatment of
pain. Devi E. Sree and co-workers24 have prepared pyrimidine derivatives and tested
for antimicrobial activity. Kovalenko A. L.25 synthesized and reported antifungal activity
of pyrimidine derivatives. Shiv P. Singh and co-workers26 synthesized 4-(4-pyrazolyl)-
2-aminopyrimidines and tested them for their antimicrobial activity.
S. S. Sangapure and A. M. Mulagi27 have tested the antimicrobial activity of
benzofuro[3,2-d]pyrimidine derivatives (XV). El Sayed28 and A. M. Badaway have
synthesized alkylated substituted mercapto pyrimidine derivatives (XVI) and studied
their anticancer and antineoplastic activity. H. Y. Moustafa29 have reported some


























Viney Lather and co-workers30  have been proposed to predict the anti-HIV
activity of dihydro (alkylthio) (naphthylmethyl) oxopyrimidines (XVII). These models
are capable of providing lead structures for development of potent but safe anti-HIV
agents.
Whittingham J. L. et al.31 have described pyrimidine ring as a platform for
antimalarial drug. Han G. Z. et al.32 documented the pyrimidine derivatives as anticancer
actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast
cancer. Tack D. K. et al.33 reported anthracycline vs nonanthracycline therapy for breast
cancer. Cano-Soldado P. et al.34 have described pyrimidine nucleus as an inhibitors of
HIV-1 reverse transcriptase. Gompel M. et al.35 have isolated  pyrimidine derivatives,a
new family of protein kinase inhibitors from the ascidian aplidium meridianum. Junmei
Wang et al.36 have prepared pyrimidine (XVIII) as HIV-1 Reverse Transcriptase.
Shimizu T. co-workers37 have described N3-substituted pyridine and related
pyrimidine nucleosides as antinociceptive effects in mice. Sanmartin C. et al.38 have
prepared new symmetrical derivatives as cytotoxic agents and apoptosis inducers.


















Mai  A.  e t  a l . 40 have  synthes ized  5-a lkyl -2-a lkylamino-6-(2 ,6-
difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-
spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family.
Yamamoto I. et al.41 have reported some oxopyrimidines searching for the novel
antagonist or agonist of barbiturates to the sleep mechanism based on the uridine
receptor. Huang Y.L. et al.42 have synthesized non classical antifolates, 5-(N-
phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-diamino-6(5H)-oxopyrimidines
as antitumor activity.
Shigeta S. et al.43 have been synthesized 5-alkyl-2-thiopyrimidine nucleoside
analogues and examined for antiviral activities against Herps Simplex virus (HSV),
Varicella-Zoster virus (SZV) and Human Cytomegalo virus (HCMV).
Herve Ganeste and co-workers44 synthesized substituted 1H-pyrimidin-2-one
(XIX) with selective dopamine D3-receptor antagonists activity.
Sanjay batra et al.45 have synthesized several 1-(2-cyano-3-aryl-allyl)-3-urea
by the reaction between allylamines generated from Baylis-Hilman acetates and
substituted isocyanates and isothiocyanate. Further, their cyclization in the  presence of
a base led to the formation of 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-1H-pyrimidin-














2-(Arylcarbonylmethyl)thio-6-alpha-naphthylmethyl derivatives of dihydro
alkoxy benzyl oxopyrimidines46 (DABO) were newly found to exhibit activity against
both HIV-1 and HIV-2. The compounds were evaluated for their in vitro anti-HIV
activity in MT-4 cells.
Looking to the diversified activities exhibited and in continuation of our work on
the synthesis of biologically active heterocycles, the synthesis and biological screening
of pyrimidine derivatives have been described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[2-
(2,4-DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-
YL]-4-ARYLPYRIMIDIN-2(1H)-ONES















SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[2-(2 ,4-
DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-
2(1H)-ONES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. 6-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-
4-arylpyrimidin-2(1H)-ones  of Type (VII) have been prepared by the condensation of
(2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones
of Type (I) with urea in presence of catalytic amount of conc. HCl as shown under.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The






















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Aromatic C-H  str. 3075 3090-3030 48
C=C str. 1464 1540-1480 ,,
1094 1125-1090 ,,
1013 1070-1000 ,,
Halide C-Cl str. 785 800-600 47
Vinyl CH=CH str. 3015 3050-3000 48
oxopyri. C=O str. 1658 1672-1652 ,,
imidazo[1,2-a] C=N str. 1591 1612-1593 47
pyridine C-N str. 1146 1220-1020 ,,
IR SPECTRAL STUDIES OF 6-[2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-
a]PYRIDIN-3-YL]-4-(4-CHLOROPHENYL)PYRIMIDIN-2(1H)-ONE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency















































Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 6.2 1H singlet Ar-CH(a)     -
2 7.14 1H dd Ar-H(f)         J=6.0,J=1.2
3 7.35 4H dd           Ar-H(b,b’,c,c’)  J=9.0
4 7.52 4H multiplet Ar-H(g,h,i,j)      -
5 7.65 1H doublet Ar-H(d)  J=3.0
6 7.80 1H doublet Ar-H(e)  J=9.0




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-2(1H)-ONES
(A) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-1-arylprop-2-en-1-ones
See (A) Part-I, Section-I (C).
(B) Synthesis of 6-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-
(4-chlorophenyl)pyrimidin-2(1H)-one
To a solution of (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-
1-(4-chlorophenyl)prop-2-en-1-one (4.27gm, 0.01 mol) and urea (0.60gm, 0.01 mol)
in ethanol (15 ml) was refluxed in presence of alcoholic KOH for 12 hr. The excess
solvent was distilled off and the residue was neutralized with dilute HCl,thus the separated
solid was filtered out and crystallized from ethanol. Yield 67 %, m.p. 260oC Anal. Calcd.
for C23H13Cl3N4O Requires: C, 59.06; H, 2.80; N, 11.98 % Found: C, 59.00; H, 2.79,
N, 11.97 %.
Similarly, other 6-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-
arylpyrimidin-2(1H)-ones were prepared.The physical data are recorded in Table No.
4.
(C) Biological screening of 6-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]-4-arylpyrimidin-2(1H)-ones
Antimicrobial testing were carried out as described in (A) Part-I, Section-I (D).
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SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-2(1H)-
THIONES
Thiopyrimidines represent one of the most active classes of compounds possessing
a wide spectrum of biological activities, such as significant in vitro activity against
unrelated DNA and RNA viruses including polio viruses, diuretic, antitubercular etc.
These valid observations led us to synthesize 6-[2-(2,4-dichlorophenyl)imidazo[1,2-
a]pyridin-3-yl]-4-arylpyrimidin-2(1H)-thiones of Type (VIII) by cyclocondensation of
(2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones
of Type (I) and thiourea in presence of HCl as catalyst.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The biological





















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Aromatic C-H  str. 3045 3090-3030 47
C=C str. 1500 1540-1480  ,,
C-H  i.p. def.. 1081 1125-1090  ,,
C-H o.o.p. def.. 821 835-810  ,,
Thiopyrimidine C=S str. 1574 1590-1550 48
Imidazo[1,2,-a] C=N str. 1598 1612-1593 ,,
pyrimidine C=C str. 1540 1590-1550 ,,
C-N str. 1092 1220-1020 ,,
C-Cl str. 780 800-600 47
IR SPECTRAL STUDIES OF 6-[2-(2,4-DICHLOROPHENYL)IMIDAZO [1,2-
a]PYRIDIN-3-YL]-4-(4-CHLOROPHENYL)PYRIMIDIN-2(1H)-THIONE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency


















































Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 6.90 2H doublet Ar-CH(b,b’)  J=8.1
2 7.12 2H doublet Ar-H(c,c’)           J=7.5
3 7.32 4H multiplet   Ar-H(g,h,i,j)      -
4 7.50 1H dd Ar-H(f)         J=9.0,J=1.8
5 7.70 1H doublet Ar-H(e)  J=9.0
6 8.00 1H singlet Ar-H(a)     -
7 8.3 1H doublet Ar-CH(d) J=6.0




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz


































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]-4-ARYLPYRIMIDIN-2(1H)-
THIONES
(A) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-1-arylprop-2-en-1-ones
See (A) Part-I, Section-I (C).
(B) Synthesis of 6-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-
(4-chlorophenyl)pyrimidin-2(1H)-thione
A mixture of (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-
(4-chlorophenyl)prop-2-en-1-one (4.27gm, 0.01 mole) and thiourea (0.78gm, 0.01 mol)
in  methanol (15 ml) was refluxed on oil-bath in presence of alcoholic KOH for 10 hr.
The solvent was distilled off and the residue was neutralized with dilute HCl, the sepa-
rated solid was filtered out and crystallized from ethanol. Yield 71 %, m.p. 200oC Anal.
Calcd. for C23H13Cl3N4S Requires: C, 57.10; H, 2.71; N, 11.58 % Found: C, 57.00; H,
2.70, N, 11.57 %.
Similarly, other 6-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-4-
arylpyrimidin-2(1H)-thiones were prepared. The physical data are recorded in Table
No. 5.
(C) Biological screening of 6-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]-4-arylpyrimidin-2(1H)-thiones
Antimicrobial testing were carried out as described in (A)Part-I, Section-I(D).
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Mannich bases containing bridged N-atom exhibit pronounced biological
activities. The study of mannich reaction attracted a great deal of attention to the chemists
because it plays a vital role owing to their wide range of industrial applications. Mannich
bases are also employed as intermediate in chemical synthesis.1-3
Mannich bases possess diverse pharmacological action like antibacterial,
antimalarial and analgesic. Several therapeutic important molecules prepared through
mannich reactions have received more attention in recent years.4-6 Mannich bases have
gained important because of their technological applications in polymer chemistry,7
especially as paints and surface active agents and exhibits complexation characteristic
with many transition metal ions.
Over the years there has been much controversy about the mechanism of the































N R2 + H +





Different methods have cited in literature to synthesize mannich bases by several
workers8,9 using various interesting substrates.
1. Seshaiah Krishnan et al.10 have synthesized mannich bases from the schiff base




2. Yung-son Hon  et al.11 have prepared mannich bases from the reaction of phenolic
 compounds with a preheated mixture of dibromomethane and diethylamine.
3. Pandeya and  Sriram D. Dave12  have  synthesized  mannich  bases  by  the
condensation of the acidic group of isatin with formaldehyde and secondary
amines.
4. Venkatesha Prabhu G. et al.13 have synthesized aminobenzylated mannich bases





















5. Chi and co-workers14 have synthesized mannich base using 1,4,10,13-
tetraoxa-7,16-diazacyclooctadecane, formaldehyde and phenolic derivatives
in benzene.
6. Christos A. Kontogiorgis et al.15 have synthesized mannich base of
coumarine.
BIOLOGICAL IMPORTANCE
Mannich bases are associated with a wide variety of biological activities and
industrial applications such as,
1. Antiinflammatory16-18

























J. Knoll et al.29 have prepared the mannich base (I) which was the most potent
neuroleptic compound of a series of aryl substituted analogues. Molindone30 (II) which
has been reported to demostrate potent neuroleptic activity. Jan Balzarini and co-
workers31 have prepared the mannich base of chalcone shows cytotoxic activities.
                     (I)                                                   (II)
B.Shivarama Holla et al.32 have prepared mannich bases (III) and tested them
for anthelmintic activity and all the newly synthesized compounds (IV) were tested for
their antibacterial and antifungal activity.
 (III)                                                              (IV)
Amodiaquine33,34, a mannich base derivative (V), which shown an antimalarial
activity superior than chloroquine in areas of high  chloroquine resistance. M. L. Edwards
et al.35 have prepared the mannich base of  4-phenyl-3-buten-2-one as an antiherps
agent. Malcolm K. Scott and co-workers36 have prepared the pyrrole mannich base

































             (VI)
Movrin M., Maysinger D. et al.37 have synthesized mannich bases from nitroxoline
and reported them as biologically active agents. Gul H. I. et al.38 have reported antifungal
activity of some mono, bis and quaternary mannich bases derived from acetophenone.
Li Y, Yang Z. S. et al.39 have synthesized some mannich base derivatives and reported
their antimalarial activity.
Lorand T. and Kocsis B.40 have synthesized some new mannich ketones and
reported their antibacterial activity. Erol D. D. et al.41 have synthesized some novel
mannich base derivatives from 6-acyl-3-(3,5-dimethylpiperidino methyl)-2(3H)-
benzooxazolones and reported their biological activities. H.M.Hassan and S.A.M.
Shedid42 have synthesized some new mannich bases and reported antimicrobial activity
of some novel mannich bases containing 1,8-napthpyridine moiety.
Ojanen T. et al.43 have documented antifungal activity of bis mannich bases derived
from acetophenones. Calis U. et al.44 have synthesized some mono mannich bases and
evaluate their anticonvulsant activity. Shingare M. S. et al.45 have described the synthesis




















R= H,4-Me, 5-OMe, 5-Cl, 6-Br
H.S.Joshi et al.46 have been synthesized some novel amino benzylated mannich
bases and reported  their antimicrobial activities.
In view of the importance of mannich bases as versatile synthetic intermediates
and the availability of scanty literature on therapeutic properties, we have undertaken


















SYNTHESIS AND BIOLOGICAL SCREENING OF  N -{ [2- (2 ,4-
DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N ,N-
DIARYL/ALKYLAMINES
In view of getting better therapeutic agent and considering the association of
various biological activity with imidazo[1,2-a]pyridine  nucleus, the preparation of
mannich bases of Type(VI) have been undertaken from 2-(2,4-dichlorophenyl)
imidazo[1,2-a]pyridine with primary /secondary amines and formaldehyde in methanol.
The constitution of newly synthesized compounds have been supported by using
elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of allthe compounds have been checked by thin
layer chromatography.
All the compounds have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activity of the synthesized compounds have been compared with standard
drugs. Some compounds have been found to have moderate activity as compared to
known antibiotics recorded on Graphical Chart No.6.
















IR SPECTRAL STUDIES OF 2-(2 ,4-DICHLOROPHENYL)-3-
(MORPHOLIN-4-YLMETHYL)IMIDAZO[1,2-a]PYRIDINE
 Observed
Alkane   C-H str. (asym.) 2962 2975-2950 47
-CH2   C-H str. (sym.) 2852 2880-2860  ,,
  C-H i.p.def. (asym.) 1460 1470-1435  ,,
  C-H o.o.p.def. 1378 1395-1370 ,,
Aromatic   C-H  str. 3044 3090-3030 48
  C=C str. 1555 1540-1480  ,,
  C-H i.p.def. 1105 1125-1000 ,,
  C-H o.o.p. (def) 826 835-810  ,,
Imidazo[1,2-a]   C=N str. 1605 1612-1593 47
pyridine   C-N str. 1197 1220-1020  ,,
  C=C str. 1495 1540-1480  ,,
  C-Cl str. 778 800-600 ,,
Ether   C-O-C str. 1231 1260-1200 48
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range


















































   1.          2.29   4H triplet           C -H(b,b’)         -
   2.          3.60   4H triplet           C-H(a,a’)         -
   3.          3.70   2H singlet           C-H(c)                      -
   4.          7.50   1H doublet           Ar-H(d)      J=3
   5.          8.43   1H doublet           Ar-H(f)      J=9
   6.          6.82   1H dd           Ar-H(e)  J=6, J=1.6




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 2-(2,4-DICHLOROPHENYL)-3-(MORPHOLIN-
4-YLMETHYL)IMIDAZO[1,2-a]PYRIDINE










































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-{[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N,N-DIARYL/ALKYL
AMINES
[A]      Preparation of  2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridine
          See (A) Part-I, Section-I (A)
[B] Preparation of  2-(2,4-Dichlorophenyl)-3-(morpholin-4-ylmethyl)imidazo[1,2-
a]pyridine
To a solution of 2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine (2.63g, 0.01 mol),
formaldehyde (0.3g, 0.01 mol) and morpholine (0.88g, 0.01 mol) in methanol (50 ml)
was added and stirred for 8 hr. and left overnight in a freeze. The content was poured on
to crushed ice. The product was isolated, dried and crystallised from hexane Yield 60%,
m.p. 140oC. Anal. Calcd. For C18H17Cl2N3O : C, 59.68; H, 4.73; N, 11.60 %; Found:
C, 59.65; H, 4.70; N, 11.61 %.
Similarly other amines condensed with 2-(2,4-dichlorophenyl)imidazo[1,2-
a]pyridine. The physical constants are recorded in Table No.6.
[C] Biological screening of N-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methyl}-N,N-diaryl/alkylamines
Antimicrobial testing was carried out as described in (A) Part-I, Section-I (D).
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Isoxazole is a five membered heterocyclic compound having two hetero atom:
oxygen at position 1 and nitrogen at position 2. In 1888, Claisen first reported an isoxazole
(I) for a product from the reaction of 1,3 diketone with hydroxylamine.1 Subsequently a
solid foundation for the chemistry of isoxazole was laid down by Claisen and his students.
It was shown to possess typical properties of an aromatic system but under certain
reaction conditions. Particularly in reducing or basic media, it becomes very highly labile.
The next important contribution to the chemistry of isoxazoles was made by
Quelico2 in 1945, when he begain to study the formation of isoxazoles from nitrile N-
oxide and unsaturated compounds.
SYNTHETIC ASPECT
Isoxazoles can be prepared by various method, which are described as under.
1. Dawood Kamal et al.3 have prepared isoxazole derivatives from enamino
nitriles.
2. Tayade V. B. et al.4 synthesized some new 3,5-diarylisoxazoles from the
reaction of 2-aryl acetophenones with hydroxyl amine hydrochloride in
presence of alkali.
3. Crawley L.  S.  and Fanshawe W. J .5 were prepared isoxazole(II)  f rom

















4. Keisuke Suzuki et al.6 have synthesized functionalized isoxazole (III) derivatives














5. Mark Lautens and Ame´lie Roy7 have constructed isoxazoles (IV), were achieved















6. Solid phase synthesis of isoxazole derivatives based on aminoacids was reported
by Lidia De Luca and co-workers8 in the presence of basic catalyst and dichloro
methane used as a solvent. One-Pot synthesis of  polyfunctionalized isoxazoles9
have been prepared by the reaction of dipyrrolidinium 3,3-dimethylpentanedinitrile
-2,4-dinitronate and acetyl chloride in benzene.
7. A variety of 3,5-disubstituted 4-bromoisoxazoles (IV)10 were prepared in good





























































































Stefano Chimichi and co-workers36 have investigated cytotoxic activity of 3-
quinolinoyl isoxazoles (VI) against leukemia and adenocarcinoma derived cell lines in
comparison to the normal human keratinocytes. Novel cyclohexyl drug resistance











 (VI)  (VII)
Julia Kaffy et al.38 have been synthesized various five membered heterocycles
with oxygen and nitrogen atoms. The 4,5 diarylisoxazole (VIII) exhibited greater
antitubulin activity, but modest antiproliferative activity. Kaifan Cheng and Yousef Al-
Abed39 have reported isoxazole derivatives (IX) have found 20-Fold more potent than
3-(4-hydroxyphenyl)-4,5-dihydro-5-acetic acid methyl ester isoxazole inhibits MIF























Aicher Thomas D. et al.40 reported isoxazoles (X) as hypoglycemic agents. H.
H. Parekh et al.41 have synthesized 3-(p-methoxyphenyl)-5-(2'-chloro-7'-methylquinolin-












Moreover, S. Rung and D. Dus42 have synthesized some new isoxazoles as
remedy for leukemia. M. Scobie and co-workers43 have prepared isoxazole  derivatives
and studied their antitumor activity. G. Daidone et al.44 synthesized novel 3-(isoxazol-3-
yl)-quinazolin-4-(3H)-one derivatives and tested for their  analgesic and
antiinflammatory activities as well as for their acute toxicity and ulcerogenic effect.
Salter M. W. et al.45 have prepared some novel isoxazoles as cellular neuroplasticity
mechanisms mediating pain persistence. Matringe M. et al.46 have reported some new
p-hydroxyphenylpyruvates dioxygenase inhibitor-resistant plants. Mehlisch D. R. et al.47
have synthesized isoxazole derivatives as analgesic efficacy of intramuscular parecoxib
sodium in postoperative dental pain. Ray W. A. et al.48 have reported isoxazole
derivatives as cardiovascular toxicity of valdecoxib.
H. S. Joshi et al.49 have synthesized isoxazole derivatives (XII) and reported









Welsing P. M. et al.50 have documented the isoxazoles as tumornecrosis factor
blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Bingham S. J. et al.51 have synthesized isoxazole derivatives as an antiuclear agents.
Barbachyn M. R. et al.52 have described the phenylisoxazolines as novel and viable
antibacterial agents active against Gram-positive pathogens.
Masui et al.53 have prepared isoxazoles having pesticidal activity. Some excellent
herbicidal results obtained by Reddy et al.54 C. B. Xue et al.55 have reported an oral
antiplatelet effect in dogs.
With an intension of preparing the compounds possessing better therapeutic
activity, we have under taken the preparation of isoxazoles bearing imidazo[1,2-a]pyridine
derivatives which have been described as follows.
SECTION-I  :   SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(2,4-
    DICHLOROPHENYL)-3-(3-ARYLISOXAZOL-5-YL)





SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - (2 ,4 -DICHLORO
PHENYL)-3-(3-ARYLISOXAZOL-5-YL)IMIDAZO[1,2-a]PYRIDINES
Isoxazoles have been reported to have various pharmacological activities like
antibacterial, antifungal, insecticidal etc. In order to achieving better drug potency, we
have prepared isoxazole derivatives of Type (VII) by the cyclocondensation of (2E)-3-
[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-1-arylprop-2-en-1-ones of Type
(I) with hydroxylamine hydrochloride in presence of sodium acetate in glacial aletic acid.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The




















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Aromatic C-H  str. 3048 3090-3030 57
C=C str. 1506 1540-1480  ,,
C-H o.o.p. def. 812 835-810 ,,
Halide C-Cl str. 799 800-600 56
C-O str. 1045 1050-1040 ,,
Isoxazole C=C str. 1655 1680-1550 57
C=N str. 1543 1690-1460  ,,
N-O str. 827 850-810  ,,
Imidazo[1,2-a] C=N str. 1598 1612-1593 56
pyridine C-N str. 1094 1220-1020 ,,
IR SPECTRAL STUDIES OF 2-(2 ,4-DICHLOROPHENYL)-3-[3- (4-
CHLOROPHENYL)ISOXAZOL-5-YL]IMIDAZO[1,2-a]PYRIDINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency









































Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 2.35 3H singlet Ar-CH3     -
2 6.84 1H singlet Ar-H(c)     -
3 7.10-7.13 1H dd Ar-H(i)         J=6.2,J=2.5
4 7.34-7.54 4H multiplet    Ar-H(d,e,f,g)     -
5 7.68-7.71 2H doublet Ar-H(a,a’)   J=9.0
6 7.77-7.80 1H doublet Ar-H(j)   J=9.0
7 8.54-8.55 1H doublet Ar-H(h)   J=2.1




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz


























































































































SYNTHESIS AND BIOLOGICAL SCREENING OF 2 - ( 2 , 4 -
DICHLOROPHENYL)-3-(3-ARYLISOXAZOL-5-YL) I M I D A Z O [ 1 , 2 -
a]PYRIDINES
(A) Synthesis of (2E)-3-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]-1-arylprop-2-en-1-ones
See (A) Part-I, Section-I (C).
(B) Synthesis of 2-(2,4-Dichlorophenyl)-3-[3-(4-chlorophenyl)isoxazol-5-
yl]imidazo[1,2-a]pyridine
To a solution of (2E)-3-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl]-
1-(4-chlorophenyl)prop-2-en-1-ones (4.27 gm, 0.01 mol) in ethanol (25 ml), anhydrous
sodium acetate (0.739gm, 0.01 mol) and hydroxylamine hydrochloride (0.59 gm, 0.01
mol) in acetic acid were added. The reaction mixture was refluxed on oil bath for 7-8 hr.
The product  was isolated and crystallized from ethanol. Yield 54 %, m.p. 160oC Anal.
Calcd. For C22H12Cl3N3O Requires ; C, 59.96; H, 2.74; N, 9.53; Found C, 59.94, H,
2.73; N, 9.52%.
Similarly, other 2-(2,4-dichlorophenyl)-3-(3-arylisoxazol-5-yl)imidazo
[1,2-a]pyridines were prepared. The physical data are recorded in Table No.7.
(C) Biological screening of 2- (2 ,4-Dichlorophenyl) -3-(3-aryl isoxazol-
5-yl) imidazo[1,2-a ]pyridines
Antimicrobial testing were carried out as described in (A) Part-I Section-1 (D).
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Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also
known as Schiff’s base and they are well known interemediate for the preparation of
azetidinone, thiazolidinone, formazone, arylacetamide and many other derivatives.  These
are the compounds contain characteristic -C=N group. Holla, B. S. et. al.1 have
















Azomethines are obtained mainly by warming the aldehyde and aromatic amine
togethar. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by trace of acid in
other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT :
1.  General account of the summary of reaction of aldehydes with amine
 (aromatic or aliphatic) has been reviewed by Murray.2
 R-CHO R'-NH2 R-CH=N-R'+
2. Oddo and Tognacchini3 have introduced the comparative rates of formation
of Schiff’s base from aniline and substituted aniline and aromatic aldehyde.





a.  Addition of the amine to the carbonyl group of the aldehyde gives aldol.
The aldol is rarely capable of isolation.
 R-CHO R'-NH2+ R-CHOHNHR'
b. The loss of water to give an imine (azomethine), this corresponds to
the “crotonaldehyde stage” of the aldol condensation.
R-CH=N-R'R-CHOHNHR' + H2O
Pierre L. Beaulieu and co-workers6 have synthesized (E)-N-phenyl
methyleneglycineethyl ester by the cyclocondensation of  glycine ethyl ester
hydrochloride, t-butylmethyl ether (TBME), benzaldehyde was added followed by
anhydrous Na2SO4 and triethylamine.
Amanda J. Gallant et al.7 have prepared schiff bases by condensation of equimolar
















Schiff bases exhibit a wide range of pharmacological activities like antifungual,
antibacterial, antiviral, antiinflammatory etc. Mehta R. H. et al.8 have synthesized
coummarin schiff’s base derivatives (II) and examined for their antibacterial activity.
Khalafallah A. K. and Hassan M. E.9 have prepared some styryl Schiff’s bases spiro










Deshmukh M. D. and Doshi A. G.11 prepared some new  Schiff ’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse
and Salmonella typhi. Wang et al.12 have synthesized diazomethines having good plant
hormone activity. Das Arima et al.13 have prepared Schiff’s bases of  aminohydroxy
guanidine (SB-AHG5) and tested  for antiviral  activity against Herpes Simplex virus
Type I (HSV-1) and adenovirus Type-5 (Ad-5).
Ali, yousif et al.14 have synthesized some Schiff’s base derivatives of glucose
containing acetylenic bond. The prepared Schiff base were tested for their bactericidal
activity against E. coli and Staphylococcus aureus.
Holla B. S. et al.15 have prepared mannich bases. Pandey Taruna et al.16 prepared
azomethines and their boron complexes and screened for their antifungal  and antibacterial
properties. It is evident that azomethines along with quite toxic but their activity increased
after complexation. Omar et al.17 have determined cyclocondensation of azomethines
having good antischistosomal activity. Chohan and co-workers18,19 have synthesized a
novel class of acetyl ferrocene derived from schiff bases possess antimicrobial activity.
some azomethine derivative screened for various antibacterial strains.
R  =   Ph, 4-Br-C6H4, 4-NO2-C6H4, R  =   3,4 -OH, 3, 4-NO2







 (II)  (III)
Nabaweyal10 have synthesized some azomethine derivatives (III) having good antibacterial
activity.




 Das Joydip et al.20 have synthesized trans-N-refinylidene-n-butylamine (IV)
which found stabillized in liposomes of phophatidylcholine. The rate of formation of the
Schiff ’s base is found to decrease with increasing cholesteral concentration in the
membrane. Patel V. M.21 have synthesized some new  Schiff’s bases having good
antibacterial activity.
Ram Tilak et al.22 have synthesized some Schiff’s bases, of 2-chloro phenothiazines
and screened against carrageenin-induced edema in albino rats. Cascaval Alexandru et
al.23 have synthesized azomethines, which have good analgesic and antipyretic properties.
Pandeya S. N. et al.24 have synthesized Schiff  bases showed good activity against Vibrio
cholerae non-o., Shigella boydii, Enterococcus faecalis and Edwaredsiella torla with
MIC in the rang of 10-25 µg/ml. Some compounds were found to be active against
Salmonellal typhi and Vibro cholerae-0, (MIC 25-150 µg/ml).
Pawar et al.25 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines, and determined antibacterial
activity. Ergenc and co-workers26 have synthesised azomethine derivatives having
antifungal activity. Yadav Bodke and S. S. Sangapure27 have synthesised some
azomethines and tested for their biological activity. B. Shivarama Holla et al.28 have
prepared some new Schiff’s bases having anticancer activity.
Ravindra V. Chambhare et al.29 have prepared some azomethines and tested for
their antimicrobial activity. B. Shivarama Holla et al.30 have synthesized azomethines


















Looking to the interesting properties of azomethines, we have synthesised
some new azomethines, which have been described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL SCREENING  OF N-
{(1E)- [2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-
` a]PYRIDIN- 3-YL]METHYLENE}-N-ARYLAMINES






     SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF N-{(1E ) - [2-(2,4-DI
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-N-
ARYLAMINES
The growing patent literature of recent years demonstrates that the azomethine
derivatives are used as better therapeutic agents. In view of these findings, it appeared
of interest to synthesize Schiff’s base of the Type  (VIII) by the condensation of  2-
(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde  with various aromatic
amines in order to study their biodynamic behavior.
The constitution of the synthesised products have been characterised by using
elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.














Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2965 2975-2950 31
-CH3 C-H str. (sym.) 2871 2880-2860   ,,
C-H def. (asym.) 1462 1470-1435   ,,
C-H def. (sym.) 1370 1390-1370   ,,
Aromatic C-H  str. 3048 3090-3030 32
C=C str. 1499 1540-1480   ,,
Halide C-Cl str. 751 800-600 31
Schiff base C=N str. 1622 1660-1580 32
Imidazo[1,2-a] C=N str. 1590 1612-1593 31
pyridine C-N str. 1100 1220-1020   ,,
IR SPECTRAL STUDIES OF N - { ( 1 E ) - [ 2 - ( 2 , 4 - DICHLOROPHENYL)
I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] M E T H Y L E N E } - N - ( 4 - M E T H Y L
PHENYL)AMINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency











































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF  N -{ (1E ) - [2- (2 ,4-DICHLOROPHENYL)
I M I D A Z O [ 1 , 2 - a ] P Y R I D I N - 3 - Y L ] M E T H Y L E N E } - N - ( 4 - M E T H Y L
PHENYL)AMINE
       1. 2.35          3H       singlet       Ar-CH3 -
       2. 8.46          1H       singlet       Ar-CH (d) -
       3. 7.06-7.12          4H     multiplet       Ar-CH -
     (h, i, j, k)
       4. 7.34-7.38          1H        doublet      Ar-CH (e)        J=1.5
       5. 7.43-7.55          2H      multiplet   Ar-CH (g,f) -
       6. 7.74-7.77          2H        doublet  Ar-CH (b,b’)         J=9



































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-{(1E)-[2-(2,4-DI
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-N-
ARYLAMINES
[A] Synthesis of 2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridine-3 carbaldehyde
See, Part-I, Section-I (B).
[B] Synthesis of  N-{(1E)-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methylene}-N-(4-methylphenyl)amine
A mixture of 2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-3 carbaldehyde
(2.91g, 0.01M) and p-toludine(1.07g, 0.01M) in ethanol (20 ml) was refluxed in
presence of glacial aceticacid in catalytic amount for 6 hr. The content was cooled and
product isolated was crystallised from ethanol. Yield, 65%, m.p. 190oC, C21H15Cl2N3   ;
Found : C, 66.33%; H, 3.98%; N,11.05%; Requires : C, 66.31%; H, 3.97%; N, 11.00%).
Similarly, other N-{(1E)-[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-N-arylamines were prepared. The physical constants are recorded in Table
No. 8.
[D] Biological screening of  N-{(1E)-[2-(2,4-Dichlorophenyl)imidazo[1,2-
  a]pyridin-3-yl]methylene}-N-arylamine
 Antimicrobial testing was carried out as described in Part-I, Section-II (D). The
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SYNTHESIS AND BIOLOGICAL SCREENING OF N-{[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N- ARYLAMINES
Aminomethyl derivatives of heterocyclic compounds are associated with diverse
biological  activities. These finding prompted us to synthesize some representative
aminomethyl derivative of Type (IX) bearing imidazo[1,2-a]pyridine moiety obtained by
selective reduction of (imine group) Schiff’s bases of  Type (VIII) with  sodium
borohydride in controlled experimental condition as shown in the reaction  scheme.
The constitution of the synthesised products have been characterised by using
elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also.
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 mg/ml. The biological
activities of the synthesised compounds were compared with standard drugs.


















Type    Vibration Frequency in cm-1 Ref.
    Mode                   Observed          Reported
Alkane C-H str. (asym.) 2969 2975-2950 31
-CH3 C-H str. (sym.) 2874 2880-2860   ,,
C-H def. (asym.) 1444 1470-1435   ,,
C-H def. (sym.) 1370 1390-1370   ,,
Aromatic C-H  str. 3084 3090-3030 32
C=C str. 1500 1540-1480   ,,
1101 1125-1090   ,,
Halide C-Cl str. 757 800-600 31
Imidazo[1,2-a] C=N str. 1588 1612-1593 32
pyridine C-N str. 1045 1220-1020   ,,
Amine N-H str. 3357 3400-3200   ,,
IR SPECTRAL STUDIES OF N -{ [2- (2 ,4-DICHLOROPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N-(4-METHYLPHENYL)
AMINE
Instrument : SHIMADZU  FTIR  8400 Spectrophotometer;  Frequency

















































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF N-{[2-(2,4-DICHLOROPHENYL)IMIDAZO
[1,2-a]PYRIDIN-3-YL]METHYL}-N-(4-METHYLPHENYL)AMINE
       1. 2.3          3H       singlet       Ar-CH3 -
       2. 4.48          2H       singlet       C-CH2 (d) -
       3. 7.06-7.18          4H     multiplet       Ar-CH -
     (e,f,g,h)
       4. 7.35-7.38          1H        doublet      Ar-CH (i)        J=1.7
       5. 7.43-7.55          2H      multiplet   Ar-CH (j,k) -
       6. 7.74-7.77          2H        doublet  Ar-CH (a,a’)         J=9
       7. 8.96          1H        singlet      Ar-NH(c)































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-{[2-(2,4-DICHLORO
PHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYL}-N- ARYLAMINES
[A] Synthesis of  N-{(1E)-[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methylene}-N-(4-methylphenyl)amine
See, Part-VI, Section-I (B).
[B] Synthesis of N-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3- yl]
  methyl}-N- (4-methylphenyl)amine
To a methanolic solution of N-{(1E)-[2-(2,4-dichlorophenyl)imidazo[1,2-
a]pyridin-3-yl]methylene}-N-(4-methylphenyl)amine (0.01M, 3.80 g), sodium
borohydride (0.15M, 0.57g) was added over a period of  30 minutes at temperature 5-
10 oC. The reaction mixture was  then kept over night at room temp. The excess
borohydride was neutralized by adding water and the product was extracted with ether.
The ether extract was washed with water untill neutral, then dried over anhydrous
Na2SO4 and finally  the ether  was evaportated  to give aminomethyl derivatives.  Yield,
61%, m.p. 200oC, C21H17Cl2N3; Found : C, 65.98%; H, 4.48%; N, 10.99%; Requires
: C, 65.96%; H, 4.47%; N, 10.98%.
Similarly, other N-{[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-yl] methyl}-
N- arylamines were prepared. The physical constants are recorded in Table No. 9.
[D] Biological screening of N-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
3-yl]methyl}-N- arylamines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
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B. Coccus 14 12 18 17 16 11 17 12 10 17 16 20 25 18 20 22 0
S. aureus 16 12 11 19 17 13 17 16 13 18 12 12 25 19 15 21 0
Aerogenes 17 9 18 10 13 20 15 18 13 14 19 17 20 21 22 19 0
Pseudomonas 13 14 10 17 12 14 12 10 10 13 16 22 22 21 16 23 0
A.niger 14 16 19 14 12 15 18 16 19 17 19 15 0 0 0 0 26
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Imidazolinone is a five membered heterocycle having 2-nitrogen atoms at 1 and
3 positions and C=O group at following positions : 2-oxo-imidazoline (I), 4-oxo-
imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888,
when A. W. Hoffman1 for the first time discovered 5-oxo-imidazoline by heating N1-
diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover, some
compounds were prepared by A. Ladenburg2 by the fusion of two equivalents of sodium
acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
literature.3 Aminolysis of oxazolone with amine leads to the formation of imidazolinones
which has been reported in literature.4
1. Allimony et al.5 have synthesized new imidazolinone derivatives by
conventional method.
2. Feng Jun Cai et al.6 have reported 5-imidazolinone derivatives by
microwaves irradiation.
3. A. Saxena et al.7 have synthesized new imidazolinones as under.










































4. Hisato Takeuchi et al.8 have synthesized imidazolinones by the reaction of
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MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the
condensation of azalactone and primary amines can be converted into imidazolinones as
shown in equation (IV). The ring closer can be affected under a variety of conditions.


















(a) (b)    (c)






Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline
and phenotolamine as adrenergic blocking agents. Various imidazolinones are known to









9. Sedative and hypnotics22
10. Anticancer23, 24
11. Antimicrobial25






Christopher Preston and co-workers35 have reported the triazolopyrimidine and
imidazolinone as herbicides. U. Akyoshi et al.36 have prepared some new imidazolinone
derivatives (V) and reported their herbicidal activity. Agrochemical activity of




Moreover Yoneda Naoto et al.38 have synthesized imidazolinones as
antihypertensive agent. R. C. Dage et al.39 have documented cardiotonic imidazolones.
Rossello et al.40 have prepared imidazolones as antifungal agent. Cooper A. B. and
co-workers41 have found that imidazolones are inhibitors of farnesyl protein transferase.
Machii Daisuke et al.42 have synthesized new imidazolones as a telomeres inhibitors and
antitumor agents. Jean M. R. et al.43 have synthesized imidazolones and tested as
antileishmanial agent. Chafiq amdouchi et al.44 have reported imidazolinones and screened













K. K. Awasthi et al.45 have synthesized some new imidazolinone derivatives (VI)
and reported their antimicrobial activity. A. J. Baxi and co-workers46 have synthesized
several imidazolinone derivatives by the condensation of some known sulpha drugs with
5-oxazolone derivatives, products have been screened for their in vitro growth























Xu Zhi-Feng et al.48 have synthesized imidazolinones as biological agent.
Farmshow Christopher Geoffrey et al.49 and Pilkington et al.50 have described and
studied antifungal activity of imidazolinones. L. Joseph Peter and co-workers51 have
prepared substituted imidazolinones which inhibited the abnormal cell growth in human
body. Stefama Lauter and co-workers52 have isolated imidazoline from different
methods and tested for the treatment of cytokine release. Imidazoline  derivatives have
been prepared by Declera arthur and co-workers53 showing anti-HIV activity. Ding Ming
Wu et al.54 have prepared novel imidazolines and reported their antifungal activity. C.
Alister and co-workers55 have documented herbicidal activity of imidazolinone
derivatives. Aleksey N. Vasiliev et al.56 have synthesized imidazolinone derivatives (VIII)
















Kolhe Vishnu et al.57 have reported anti-AIDS, antibacterial and fungicidal activity
of 5-oxo-imidazolines. B. R. Shah and co-workers58 have prepared some new
imidazolines and reported anticancer and anti HIV activity.
With a view to getting better therapeutic agent, it was contemplated to synthesize
imidazolinones to enhance the overall activity of resulting compounds which have been
described as under.
SECTION - I   :    SYNTHESIS AND BIOLOGICAL SCREENING OF (5Z)-5-
        {[2-(2,4-DICHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-
        3-YL]METHYLENE}-3-ARYL-2-PHENYL-3,5-DIHYDRO-





SYNTHESIS AND BIOLOGICAL SCREENING OF (5Z ) -5 - { [2 - (2 ,4 -DI
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
Imidazolinones represent one of the most active class of compounds having a
wide spectrum of biological activities. With an aim to getting better therapeutic agent,
the preparation of (5Z)-5-{[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones of Type (X) have been
undertaken by the condensation of azalactone with different aromatic amines as shown
in reaction scheme.
The constitution of the synthesized products have been characterized by using
elemental analysis, infra red and 1H-nuclear magnetic resonance spectroscopy and further
supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesized compounds were compared with standard drugs.
The details have been cited in (A) Part-I, Section-I (D).

























Alkane   C-H str. (asym.) 2960 2975-2950 59
-CH3   C-H str. (sym.) 2852 2880-2860  ,,
  C-H i.p.def. (asym.) 1442 1470-1435  ,,
Aromatic   C-H  str. 3048 3090-3030 60
  C=C str. 1514 1540-1480  ,,
  C-H o.o.p. (def) 820 835-810  ,,
Imidazo[1,2-a]   C=N str. 1638 1600-1650  ,,
pyridine   C-N str. 1143 1220-1020  ,,
Imidazole   C=O str. 1658 1760-1655 59
ring   C=N str. 1570 1650-1580  ,,
  C=C str. 1492 1540-1480  ,,
Halide   C-Cl str. 706 800-600 60
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range












































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF (5Z)-5-{[2-(2,4-DICHLOROPHENYL)
IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-3-(4-METHYLPHENYL)-2-
PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONE






















b'       1. 2.309   3H singlet      Ar-CH3 -
       2. 6.8-7.1   3H multiplet      Ar-H(n,o,p) -
       3. 7.1-7.7   9H multiplet      Ar-H -
       (d,e,f,g,h,j,k,l,m)
       4. 7.72-7.85    2H doublet      Ar-H (b,b’) J=9
       5. 7.87-7.95    2H doublet      Ar-H (c,c’) J=6.2































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF (5Z ) -5 - { [2 - (2 ,4 -DI
CHLOROPHENYL)IMIDAZO[1,2-a]PYRIDIN-3-YL]METHYLENE}-3-ARYL-
2-PHENYL-3,5-DIHYDRO-4H-IMIDAZOL-4-ONES
[A] Synthesis of 2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
See (A)Part-I, Section-I (B).
[B] Synthesis of  (4Z)-4-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-2-phenyl-1,3-oxazol-5(4H)-one
A mixture of  2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridine-3-carbaldehyde
(2.91 gm, 0.01 mol), acetic anhydride (7.6 ml, 0.075 mol), hippuric acid (4.4gm, 0.025
mol) and sodium acetate (2.46 gm 0.03 mol) was heated on a waterbath for  4-5 hr. The
resulting solution was poured on to crushed ice, filtered and crystallized from dioxane.
Yield, 68%, m.p. 232oC.
[C] Synthesis of (5Z)-5-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-3-(4-methylphenyl)-2-phenyl-3,5-dihydro-4H-imidazol-4-one
To a solution of  (4Z)-4-{[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-2-phenyl-1,3-oxazol-5(4H)-one (4.34 gm, 0.01 mol) and p-toluidine
(1.27gm, 0.01 mol) in dry pyridine (25 ml) was refluxed for 12 hr. on oil bath. The
content was poured on to crushed ice and neutralized with HCl, the isolated product
crystallized from dioxane. Yield 66%, m.p. 142oC; Anal. Calcd. for C30 H20 Cl2 N4 O ;
Requires : C, 68.84; H, 3.85; N, 10.70 %; Found : C, 68.82, H, 3.84, N, 10.71 %.
Similarly other (5Z)-5-{[2-(2,4-dichlorophenyl)imidazo[1,2-a]pyridin-3-
yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-one were prepared. The
physical constants are recorded in Table No. 10.
[D] Biological screening of (5Z)-5-{[2-(2,4-Dichlorophenyl)imidazo[1,2-a]pyridin-
` 3-yl]methylene}-3-aryl-2-phenyl-3,5-dihydro-4H-imidazol-4-ones.
Antimicrobial activity was carried out as described in (A)Part-I, Section-I (D).
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Dihydroyrimidine is the most important member of all the diazines as this ring
system occurs widely in living organisms. Purines, uric acid, barbituric acid and
antimalarial, antibacterial agents also contain the dihydropyrimidine ring. The chemistry
of pyrimidine has been widely studied. Pyrimidine was first isolated by Gabriel and Colman
in 1899.  Despite the importance of dihydroazines (particularly those containing the
1,4-dihydropyrimidine and dihydropyridine moiety1) for clarifying a wide range of
theoretical, medicinal and biological problems, the chemistry of this group of compounds
is still extremely spotty. 2-6
In the area of drug development, dihydroazines show great promise,
particularly since the 4-aryldihydropyridines exhibit powerful vasodilation activity via
modifying the calcium ion membrane channel.7-11  Additionally, dihydropyridines have
been found to actively transport medication across biological membranes.12
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry, particularly dihydropyrimidines containing no substituents on the ring nitrogen.13
These molecules have long been considered unstable for oxidation, polymerization or
disproportionation reactions.14
Figure (I) depicts the five possible isomeric structures of dihydropyrimidines,




















(1) A simple effective synthesis of DHPM-2(1H)-one derivatives is using FeCl3
as catalyst by the reaction of an aldehyde, β-dicarbonyl compound and urea
thiourea.15
(2) A novel one-pot condensation of an aldehyde, b-keto-ester and urea was
performed using iodotrimethylsilane in acetonitrile for the first time at
room temperature affording DHPMs.16
(3) Recently Kappe C. O.17 demonstrated that by using neat polyphosphate
ester(PPE) as reaction mediator coupled with microwave irradiation,
excellent yield of variously substituted DHPMs can be obtain.
(4) Reddy et al.18 described practical rout for the Biginelli reaction using zirconium
tetrachloride as a catalyst. Three component condensation reaction of an aromatic
aldehyde, β-ketoester and urea thiourea in ethanol afforded the corresponding
DHPM-2-(1H)-ones in high yield.
(5) Shingare M. S. et al.19,20 examined a simple but effective procedure for
Biginelli condensation reaction of an aldehyde, β−ketoester and urea thio




























Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and  stimulus-secretion.21-23 In recent years interest has also
focused on aza-analogs such as dihydropyrimidines (I) which show a very similar
pharmacological profile to classical dihydropyridine calcium channel modulators.24-30
Hidetsura Cho et al.24 have synthesized the novel calcium channel antagonists 3-
N-substituted-3,4-dihydropyrimidines and 3-N-substituted-dihydropyrimidin-2(1H)-
ones were regioselectively synthesized in good yields. Efforts of Atwal  K. S. et al.31 in





























Dhanapalan N. et al.32  prepared dihydropyrimidinones (IV) exhibited high binding
affinity and subtype selectivity for the cloned human a1a receptor. James C. et al.
33
explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via
C-5 amide as selective a1a receptor subtype antagonists. Several recently isolated marine
alkaloids with  interesting biological activities also contain dihydropyrimidinone nucleus.
Frederick C. et  al.204 described that a novel class of polyguanidine alkaloids isolated

















Rakesh Kumar36 synthesized, antiviral and cytotoxic activities of 5-bromo
(or chloro)-6-azido-5,6-dihydro-20-deoxyuridine (1,2) and thymidine (3,4). Compounds



























































4-Aryl-1,2,3,4-tetrahydropyrimidin-2-one derivatives37 have been synthesized and
examined for their activity against pathogenic strains of Aspergillus fumigatus and
Candida albicans.Recently many new molecules which are under study from phase-I
to IV clinical trials for different pharmacological action have shown as under.
Literature survey reveals that dihydropyrimidine possess potential drug activity.
Looking to the diversified biological activity, it appeared of interest to synthesize some
new dihydropyrimidines, these studies are described in following parts.
PART - I    :    STUDIES ON DIHYDROPYRIMIDINONES
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Genera l ly  pyr imidine  der iva t ives  such as  d ihydropyr imidinones ,
dihydropyrimidinthiones are studied. Dihydropyrimidines have been isolated from the
hydrolysis of the nucleic acid.
Dihydroyrimidines are among those molecules that make life possible, have been
some of the building blocks of  DNA and RNA. Several analogues of  dihydropyrimidines
have been used as compounds that interfere with the synthesis and functioning of nucleic
acids e.g. fluorouracil, which has been used in cancer treatment. Also there are some
thiouracil derivatives, which produce adverse  reduction in susceptible patients and found
more potent and less likely to produce side effects and is being widely used. There are
several other important groups of dihydropyrimidines with medicinal uses.
SYNTHETIC ASPECT
(1) In 1893 Pietro Biginelli reported the first synthesis of dihydropyrimidines
(I) by a simple one-pot condensation reaction of ethyl acetoacetate, benzaldehyde
and urea under strongly acidic condition.1,2
CH3 O
EtOOC








(2) Substituted 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli
condensation of an aldehyde, dicarbonyl compounds and urea in ethanol using
CoCl2.6H2O catalyst.
3
(3) DHPM-2-(1H)-one was prepared from three component i.e. β-diketone,







(4) A simple effective synthesis of DHPM-2-(1H)-one derivatives, using boric
acid as a catalyst from an aldehyde 1,3-dicarbonyl compound and urea in
glacial acetic acid is described.6 Compared with the classical Biginelli
reaction conditions, this new method has the advantage of excellent yield
86-97% and the short reaction time (0.5-2hr).
(5) Subhas D. Bose et al.7 describe a general and practical route for the Biginelli
cyclocondensation reaction using cerium (III) chloride (CeCl3)heptahydrate
as catalyst.
(6) Recently, Indium (III) chloride was emerged as a powerful Lewis catalyst
imparting high region and chemo selectivity in various chemical transformations
Ranu C.et al.8 described a simple synthesis of DHPM-2-(1H)-one derivatives,
using indium (III) chloride (10 %) as a catalyst from an aldehyde, β-di
carbonbyl compound and urea in THF.
(7) A practical and green chemistry approach towards synthesis of DHPM-2-
(1H)-one without any solvent or catalyst.  This method was developed by
Ranu C. et al.9  Dihydropyrimidinone was prepared from three component
β-diketone, aldehyde and urea was heated under stirring at 100-105 0C
afford the corresponding DHPM-2-(1H)-one in high yield (82%) and
purity (> 95%).
(8) DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation
of an aldehyde, a dicarbonly compound and urea in ethanol using Mn(OAc)3
as a catalyst.10
(9) Oliver Kappe et al.11 have synthesized dihydropyrimidine-5-carboxylicacid
in two steps by multicomponent condensation of benzyl or allyl  β-ketoesters






Despite the importance and current interest in dihydropyrimidines of, the
mechanism of the classical three-component Biginelli condensation has not been

















The “carbenium ion mechanism” was proposed by Sweet and Fissekis,13 who
investigated the reaction in 1973 and suggested that an acid-catalyzed aldol
condensation is the first and limiting step of the Biginelli condensation. It was proposed
that under acid catalysis benzaldehyde  and ethyl acetoacetate would react in an aldol-
type fashion to produce the corresponding aldol (I), which dehydrates in the presence
of acid to the resonance-stabilized carbenium ion13-15(II).
Interception of cation (II) by urea or N-methylurea then produces ureides (III),















































Atwal K. S. et al.16 have described  the potent antihypertensive activity of the
modestly active (ICw = 3.2 pM) dihydropyrimidine calcium channel blocker. Kappe C.
O. et al.17 synthesize the polycyclic DHPM derivatives. T. G. Muralidhar et al.18 have
synthesized several DHPM-one analogues among this (II) and (III) give excellent
selectivity (>880-fold) over α1b and α1d and also showed good selectivity over






























 (II)             (III)
The 5,6-dihydropyrimidine nucleosides have attracted attention as potential
antiviral and antitumor agents.19,20 Physiological dihydro nucleosides play an important
role in nucleic acid metabolism and appear frequently in the sequence of tRNA21.  5,6-
Dihydro analogues of thymidine (IVc) can act as competitive substrates, to thymidine,
for thymidine kinase.22,23 5-Fluoro-6-hydroxy (or acetoxy)-5,6-dihydro-2’-deoxyuridine
diastereomers (IVa,b) have been investigated as prodrugs to 5-fluoro-2’-deoxyuridine.19
The 5,6-dihydro derivatives (IVd–f) of antiviral pyrimidine nucleosides as potential
prodrugs.24-29 It was observed that the groups at C-5 and C-6 positions in the 5,6-
dihydro derivatives created a potentially interesting enhancement of lipophilicity with
respect to that of the parent nucleosides. It was also found that 5,6-dihydropyrimidine
nucleosides (IVd–f) serve as slow releasers (prodrugs) of the parent nucleosides in
vivo and were stable to glycosidic bond cleavage. These beneficial properties of 5,6-




derivatives of 2’-deoxyuridine and thymidine to study their biological activity.
Victor E. M.et al.30 synthesized 5’-triphosphates of (V) and (VI) and evaluated
directly as reverse transcriptase (RT) inhibitors using both a recombinant enzyme and
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Sanjay Batra et al.31 have synthesized 5-arylmethyl-4-imino-3-aryl-3,4-dihydro-
1H-pyrimidin-2-ones which were tested for their antibacterial activity. Mai A. and
coworkers32 have investigate the dihydropyrimidines which are highly active against HIV-
1. Herve Ganeste et al.33 synthesized substituted 1H-pyrimidin-2-one with selective
dopamine D3-receptor antagonists activity.
New drug molecules under clinical study
Recently many new molecules which are under study from phase-I to IV clinical
trials for different pharmacological action have shown that the basic characteristic of
morpholine to behave as hidden amine has attracted many medicinal chemists to






























































With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidinones which have been
described in following sections
SECTION-I   : SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ISO
PROPYL-4-ARYL-2-OXO-N-PHENYL-1,2,3,4-TETRAHYDRO
PYRIMIDINE-5-CARBOXAMIDES







SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ISOPROPYL-4-ARYL-2-
OXO-N-PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDES
Much interest have been focused around dihydropyrimidinone derivatives because
of their wide variety of pharmacological properties and industrial applications. In view
of these findings and achieve to better drug potency, we have synthesized 6-isopropyl-
4-aryl-2-oxo-N-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamides of Type (XI) by the
condensation of 4-methyl-3-oxo-N-phenylpentanamide with urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The



















































Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2958 2975-2950    37
-CH3 C-H str. (sym.) 2865 2880-2860     ,,
C-H i.p.def. (asym.) 1439 1470-1435     ,,
C-H o.o.p. def. (sym.) 1378 1390-1370     ,,
Aromatic C-H  str. 3081 3090-3030    38
C=C str. 1534 1540-1480     ,,
Pyrimidine C=C str. 1572 1580-1520     ,,
moity C-H str. 3025 3080-3030     ,,
C-H i.p. def. 1058 1125-1090     ,,
Amide -NH str. 3397 3410-3380     37
-NH def. 1605 1635-1595     ,,
Carbonyl            -C=O str. 1710 1700-1725     ,,
 Amide               - C=O str. 1677 1690-1660             ,,
Isopropyl C-H str. 1371 1385-1365      ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
















































Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER
Spectrometer (300 MHz)
1 1.62 3H singlet C-CH3(a) -
2 1.81 3H singlet C-CH3(b) -
3 2.33 3H singlet Ar-CH3(d) -
4 3.79 1H singlet C-CH(c) -
5 5.39 1H doublet Ar-CH(k) J=3.6
6 6.87 1H singlet Ar-NH(g) -
7 7.12-7.07 5H multiplet Ar-CH -
(j,k,l,m,n)
8 7.35 2H doublet Ar-CH(i,i’) J=6.4
9 7.47 2H doublet Ar-CH(h,h’) J=9.0
10 7.56 1H singlet Ar-NH(e)




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz












































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF  6-ISOPROPYL-4-ARYL-2-
OXO-N-PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDES
(A) Synthesis of 4-Methyl-3-oxo-N-phenylpentanamide
           A mixture of methyl 4-methyl-3-oxopentanoate (methyl isobutrylacetate) (1.44
gm, 0.01 mol) and aniline (0.93 gm, 0.01 mol) in toluene containing few drops of ethylene
diamine was refluxed for 12 hr and collect methanol using dean and stark. The resulting
solution was cooled to 00C. Than add dilute HCL solution in toluene layer, the seperated
toluene layer washed with three times water. and distilled out under vaccum. Yield 71%,
m. p. 320C, Anal.Calcd. for C12H15NO2 Calcd: C, 70.22; H, 7.37; N, 6.82%, Found:
C, 70.21; H, 7.36; N, 6.81%.
(B) Synthesis of 6-Isopropyl-4-(4-methylphenyl)-2-oxo-N-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamide
A mixture of urea (0.60 gm, 0.01 mol), 4-methyl benzaldehyde (1.20 gm, 0.01
mol) and  4-methyl-3-oxo-N-phenylpentanamide (2.05 gm, 0.01 mol) in 15 ml of ethanol
containing few drops of concentrated hydrochloric acid was refluxed for 8 hr. The solution
was allowed to stand for 12 hr. at room tempeture. The resulting solid mass separated
was filtered and, crystallized from dioxane. Yield 41%, m. p. 2660C, Anal.Calcd. for
C21H23N3O2 Calcd: C,72.18; H,6.63; N, 12.03%, Found:  C, 72.16; H, 6.62; N, 11.99
%.
Similarly, other 6-isopropyl-4-aryl-2-oxo-N-phenyl-1,2,3,4-tetrahydro
pyrimidine-5-carboxamides were prepared. The physical data are recorded in Table
No. 11
(C) Biological screening of  6-Isopropyl-4-aryl-2-oxo-N-phenyl-1,2,3,4-
tetrahydropyrimidine-5-carboxamides
Antimicrobial activity was carried out as described in (A) Part-I, Section-I(D).
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SYNTHSIS AND BIOLOGICAL SCREENING OF 6-ISOPROPYL-4-ARYL-N-
(4-METHYLPHENYL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDES
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
reports, we have synthesized 6-isopropyl-4-aryl-N-(4-methylphenyl)-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamides of Type (XII) by the condensation of 4-Methyl-
N-(4-methylphenyl)-3-oxopentanamide ,urea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The


















































Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 6-ISOPROPYL-4-PHENYL-N-(4-METHYL
PHENYL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
Alkane C-H str. (asym.) 2958 2975-2950   37
-CH3 C-H str. (sym.) 2874 2880-2860     ,,
C-H i.p.def. (asym.) 1456 1470-1435     ,,
C-H o.o.p. def. (sym.) 1388 1390-1370     ,,
Aromatic C-H  str. 3047 3090-3030    38
C=C str. 1513 1540-1480     ,,
Pyrimidine C=C str. 1578 1580-1520     ,,
moity C-H str. 3072 3080-3030     ,,
C-H i.p. def. 1101 1125-1090     ,,
Amide         -NH str. 3396 3410-3380     37
        -NH def. 1625 1635-1595     ,,
Carbonyl        -C=O str. 1706 1700-1725     ,,
 Amide           -C=O str. 1689 1690-1660          ,,
Isopropyl C-H str. 1362 1385-1365     ,,


















































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 1.52                            3H singlet C-CH3(a)       -
2 1.73 3H singlet C-CH3(b)       -
3 2.30 3H singlet Ar-CH3(d)       -
4 3.81 1H singlet C-CH(c)       -
5 5.03 1H doublet Ar-CH(l)       -
6 7.05 2H doublet Ar-CH(k,k’)    J=6.6
7 7.10 2H doublet Ar-CH(j,j’)    J=9.0
8 7.26 2H doublet Ar-CH(h,h’)    J=6.0
9 7.47 2H doublet Ar-CH(i,i’)    J=6.1
10 8.57 1H singlet Ar-NH(e)       -
11 8.93 1H doublet Ar-NH(g)       -
12 9.31 1H singlet Ar-NH(f)       -
NMR SPECTRAL STUDIES OF 6-ISOPROPYL-4-(4-CHLOROPHENYL)-N-
(4-METHYLPHENYL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
























































































   
   















































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ISOPROPYL-4-ARYL-N-
(4-METHYLPHENYL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDES
(A) Synthesis of 4-Methyl-N-(4-methylphenyl)-3-oxo-pentanamide.
 A mixture of methyl-4-methyl-3-oxopentanoate (methyl isobutrylacetate) (1.44
gm, 0.01 mol) and p-toluidine (1.07 gm, 0.01 mol) in toluene containing few drops of
ethylene diamine was refluxed for 12 hr and collect methanol using dean and stark. The
resulting solution was cooled to 00C. Add dilute HCL solution in to toluene layer, the
seperated toluene layer was washed with three times water. The toluene distilled out
under vaccum, the separated solid was crystallized from hexane-ethylacetate mixture.
Yield-65%,m.p.580C, Anal.Calcd. for C13H17NO2 Calcd: C, 71.21; H, 7.81;N,6.39,
Found:  C, 71.19; H, 7.80; N,6.40 %.
(B) Synthesis of  6-Isopropyl-4-(4-chlorophenyl)-N-(4-methylphenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide
A mixture of urea (0.60 gm, 0.01 mol), 4-chlorobenzaldehyde (1.40 gm, 0.01
mol) and 4-methyl-N-(4-methylphenyl)-3-oxo-pentanamide (2.19 gm, 0.01 mol) in 15
ml of ethanol containing few drops of concentrated hydrochloric acid was refluxed for
24 hr. The solution was allowed to stand for 12 hr. at room tempeture and the resulting
solid mass separated was filtered and crystallized from dioxane.Yield 49%, m.p.247
0C, Anal.Calcd. for C21H22CIN3O2Calcd: C,65.71; H, 5.78; N, 10.95%, Found:  C,
65.69; H, 5.77; N, 10.93 %.
Similarly, other 6-isopropyl-4-aryl-N-(4-methylphenyl)-2-oxo-1,2,3,4-tetra
hydropyrimidine-5-carboxamides were prepared. The physical data are recorded in Table No. 12
(C) Biological screening  of  6-Isopropyl-4-aryl-N-(4-methylphenyl)-2-oxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamides
Antimicrobial testing were carried out as described in (A) Part-I Section-(D).
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Thiourea itself was one of the first new drug employed to depress, the clinically
over active thyroid in thyrotoxicosis1 but some of the cyclic thiourea have been found
better suited. All of these are prone of produce adverse reduction in susceptible patients
and found more potent and less likely to produce side effect and is being used widely.2
Dihydropyrimidinthione ring carrying various subtituents may be built up from
two or three aliphatic fragments by the principle synthesis or by a variety of other
synthesis, which are complimentary rather than alternative to it. A second type of
synthesis is the isomerisation or break down of another heterocycles such as an
hydration of purine but such roots are frequently used.
From the biochemical point of view, 1,4-dihydropyrimidine are of intense
interest because of presence of this group at the active site of the “hydrogen transferring
coenzyme” NADH (reduced nicotinamide adenine dinucleotide). This nucleotide, a
central participant in metabolic processes in living organisms, participates in the
reduction of various unsaturated functionalities.
SYNTHETIC ASPECT
(1) Silica sulfuric acid efficiently catalyzes the three component Biginelli reaction
between an aldehyde, β-dicarbonyl compound, and thiourea in ethanol  to afford
the corresponding dihydropyrimidines (I) in high yield.3   The catalyst is reusable
and can be applied several times without any decrease in the yield of the reaction.
CH3 O
EtOOC













(2) DHPM was prepared from three component β-diketone, aldehyde and thiourea
coupling in ethanol catalyze by indium(III) tribromide(InBr3).
4,5  This modified
one-pot Biginelli condensation provided not only simple preparation but also this
modified Biginelli reaction was oxygen-bridge.
(3) Some Biginelli compounds were synthesized by using a photochemistry method.
The Biginelli three component cyclocondensation reaction in THF medium using
a mixture of β-ketoester or β-diketone, aryl aldehyde and thiourea under
irradiation with a tungstan lamp light to gave DHPM-2-(1H)-thiones.6
(4) Recently, Wang L. et al.7-9 developed novel one pot Biginelli-type reaction.
Aromatic or aliphatic aldehydes with β-dicarbonyl compound and thiourea in
presence of catalytic amount of 5 % of Yb(OTf)3 at 100 
0C for 60-90 minute





















Biginelli compounds show a diverse range of biological activities. As early as
1930 simple derivatives (III) were patented as agent for the protection of wool against
moths.10 Later, interest focused on the antiviral activity of Biginelli compounds.11
Pyrimidine-5-carboxamides derivatives (IV) were reported to possess
anticarcinogencic activity,12 antiinflammaroty,13 analgesic14 and blood platelet
aggregation inhibitory activity. 15
Simple modificatios of the aromatic ring are reported to give substances with
only moderate cardiovascular activity, e.g. (V)16, (VI),17,18,19 and (VII) were shown to
be potent calcium channel blockers,20-22 but they do not show any significant
antihypertensive activity20 in vivo. This is also the case for bicyclic dihydropyrimidines23,24
(V).
Among the most potent derivatives are Biginelli compounds bearing an ester group
at N-3 (VIII), there by closely resembling the nifedipine structure.25-28 Although the
calcium channel  blocking activity of these compounds, (IX) is comparable to















































Atwal K. S. et al.29 synthesized the 2-[ [ (4-methoxyphenyl)methyl]thio]-
dihydropyrimidine (X) and investigated that pyrimidines are integral parts of such
biologically important compounds as antiviral,30,31 antitumor 32 and cardiovascular agent.33
A very recent highlight in this context has been the identification of the
structurally rather simple DHPM monastrol (XI) as a novel cell-permeable molecule
that blocks normal bipolar spindle assembly in mammalian cells and therefore causes
cell cycle arrest.34 Monastrol specifically inhibits the mitotic kinesin Eg5 motor protein

































George C. et al.36 prepared dihydropyrimidine (XII) was equipotent to nifedipine
and amlodipine in vitro. In the spontaneously hypertensive rate, dihydropyrimidine (XII)
is both more potent and longer acting than nifedipine and compares most favorably with
the long-acting dihydropyridine derivative amlodipine. Dihydropyrimidine (XII) has the
potential advantage of being a single enantiomer.
Sally Ann P. et al.37 synthesized 4,6-Bis[(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4- d]pyrimidine (XIII) was identified as a novel adenosine A1
receptor antagonist, antagonizing adenosine stimulated cyclic adenosine mono
phosphate generation in guinea pig brain slices.38,39
Atwal K. et al.26 synthesized the 3-substituted 1,4-dihydropyrimidine and show
that vasorelaxant activity. Novel compounds related to 2-(cyclohexylthio)-3,4-dihydro-
5-methyl-6-(3-methy lbenzyl ) -4-  oxopyr imid ine  (XIV) (  MC 639)  have  been
s y n t h e s i z e d  b y  Antonello M. et al.40 and tested as inhibitors of Human

























Various 2-thiopyrimidine derivatives have been synthesized by Sondhi S.M. et
al.41 One of the compound, 7,7,8a-trimethyl-hexahydro-thiazolo[3,2-c]pyrimidine-5-
thione (XV) showed good antiinflammatory (37.4% at 100mg/kg p.o.) and analgesic
activity (75% at 100 mg/kg p.o.). Twenty 5-alkyl-2-thiopyrimidine nucleosides were
newly synthesized by Shigeta S. et al.42 and examined for antiviral activities against Herpes
Simplex virus (HSV), Varicella Zoster virus (VZV) and Human Cytomegalovirus
(HCMV).
Attia  A. M. et al.43 synthesized N3-beta-D-glucopyranosyl, galactopyranosyl
and xylopyranosyl 6-methyl-2-methylthiouracil (XVI) and their 5-bromo derivatives  by
coupling an α-acetobromosugar with the corresponding thiouracil. The new modified
thiouridine analogues were evaluated for their inhibitory activity against Human





























Massey A. et al.44 described the thiopurines, 6-thioguanine (XVII) and 6-
mercaptopurine (XVIII) are antileukemic agents that are incorporated into DNA
following retrieval by the purine salvage pathway.
The metabolic rate of three pharmacologically significant thiopyrimidines has been
investigated by Spector E. et al.45  Incubation of thiamylal (XXI),5-allyl-5-(1-
methylbutyl)-2-thiobarbituric acid (XXII), with minced rat liver resulted in the
formation of a metabolite which was isolated and identified as secobarbital.
With an intention of preparing the compounds possessing better therapeutic
activity, we have undertaken the synthesis of dihydropyrimidinthiones which have been
described in following sections
SECTION-I  : SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ISO
PROPYL-N-(4- METHOXYPHENYL)-4-ARYL-2-THIOXO-
1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDES































SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ISOPROPYL-N-(4-
M E T H O X Y P H E N Y L ) - 4 - A RY L - 2 - T H I O X O - 1 , 2 , 3 , 4 - T E T R A H Y D R O
PYRIMIDINE-5-CARBOXAMIDES
Much interest have been focused around dihydropyrimidinthione derivatives
because of their wide variety of pharmacological properties and industrial applications.
In view of these findings and achieve to better drug potency, we have synthesized 6-
isopropyl-N-(4-methoxyphenyl)-4-aryl-2-thioxo-1,2,3,4-tetrahydro pyrimidine-5-
carboxamides of Type (XIII) by the cyclocondensation of 4-methyl-N-(4-
methoxyphenyl)-3-oxopentanamide with thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The


























































Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 6-ISOPROPYL-N-(4-METHOXYPHENYL)-4-(3-
CHLOROPHENYL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
  Alkane C-H str. (asym.) 2958 2975-2950    46
-CH3 C-H str. (sym.) 2870 2880-2860     ,,
C-H i.p.def. (asym.) 1465 1470-1435     ,,
C-H o.o.p. def. (sym.) 1371 1390-1370     ,,
Aromatic C-H  str. 3074 3090-3030    47
C=C str. 1509 1540-1480     ,,
Pyrimidine C=C str. 1529 1580-1520     ,,
moity C-H str. 3037 3080-3030     ,,
C-H i.p. def. 1047 1125-1090     ,,
Amide -NH str. 3354 3410-3380     46
-NH def. 1597 1635-1595     ,,
Carbonyl            -C=O str. 1706 1700-1725     ,,
 Amide               - C=O str. 1649 1690-1660             ,,
Isopropyl  C-H str. 1380 1385-1365      ,,
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:






























































NMR SPECTRAL STUDY OF 6-ISOPROPYL-N-(4-METHOXYPHENYL)-4-(3-
CHLOROPHENYL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 1.54                            3H singlet C-CH3(a)       -
2 1.74 3H singlet C-CH3(b)       -
3 3.78 3H singlet Ar-OCH3(d)       -
4 3.81 1H singlet C-CH(c)       -
5 5.08 1H doublet Ar-CH(H)       -
6 6.82 2H doublet Ar-CH(I,I’)    J=9.0
7 7.15-7.32 4H multiplet Ar-CH(k,l,m,n)       -
8 7.42-7.55 2H doublet Ar-CH(j,j’)    J=9.0
9 8.43 1H singlet Ar-NH(e)       -
10 8.83 1H doublet Ar-NH(f)       -



















































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF  6-ISOPROPYL-N-(4-
M E T H O X Y P H E N Y L ) - 4 - A RY L - 2 - T H I O X O - 1 , 2 , 3 , 4 - T E T R A H Y D R O
PYRIMIDINE-5-CARBOXAMIDES
(A) Synthesis of 4-Methyl-N-(4-methoxyphenyl)-3-oxo-pentanamide
           A mixture of methyl-4-methyl-3-oxopentanoate (methyl isobutrylacetate) (1.44
gm, 0.01 mol) and 4-methoxyaniline (1.23 gm, 0.01 mol) in toluene containing few drops
of ethylene diamine was refluxed for 12 hr. The excess methanol was collected in dean
and stark. The resulting solution was cooled to 00C and trated with dilute HCL. The
seperated  toluene layer washed with three times water and distilled out under vaccum.
Yield 61%, m. p. 360C, Anal.Calcd. for C13H17NO3 Calcd: C, 66.36; H, 7.28; N,
5.95%, Found:  C, 66.33; H, 7.30; N, 5.97%.
(B) Synthesis of 6-Isopropyl-N-(4-methoxyphenyl)-4-(3-chlorophenyl)-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
A mixture of thiourea (0.76 gm, 0.01 mol), 3-chlorobenzaldehyde (1.40 gm, 0.01
mol) and 4-methyl-N-(4-methoxyphenyl)-3-oxo-pentanamide (2.35 gm, 0.01 mol) in
ethanol (15 ml ) containing few drops of concentrated hydrochloric acid was refluxed
with stirring for 24 hr. The solution was allowed to stand for 12 hr. at room temperature.
The resulting solid mass separated was filtered and crystallized from dioxane. Yield 62%,
m. p. 2500C, Anal.Calcd. for C21H22CIN3O2S Calcd: C, 60.64; H, 5.33; N, 10.10%,
Found:  C, 60.63; H, 5.32; N, 10.08%.
Similarly, other 6-isopropyl-N-(4-methoxyphenyl)-4-aryl-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamides  were prepared. The physical data are recorded
in Table No. 13
(C) Biological screening of   6-Isopropyl-N-(4-methoxyphenyl)-4-aryl-2-
thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamides
Antimicrobial testing were carried out as described in Part-I(A) Section-I(D).
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SYNTHSIS AND BIOLOGICAL SCREENING OF  N-(4-FLUOROPHENYL)-6-
ISOPROPYL-4-ARYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE- 5-
CARBOXAMIDES
Compounds containing pyrimidine ring are widely distributed in nature. Many of
these derivatives are reported to possess different biological activities. In view of these
report, we have synthesized N-(4-fluorophenyl)-6-isopropyl-4-aryl-2-thioxo-1,2,3,4-
tetrahydropyrimidine- 5-carboxamides of Type (XIV) by the condensation of 4-methyl-
N-(4-fluorohenyl)-3-oxo-pentanamide, thiourea and aryl aldehydes.
The structure elucidation of synthesized compounds has been done on the basis
of elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by Mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40µg/ml. The






















































Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF  N-(4-FLUOROPHENYL)-6-ISOPROPYL-4-(4-
FLUOROPHENYL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
 Alkane C-H str. (asym.) 2958 2975-2950    46
-CH3 C-H str. (sym.) 2875 2880-2860     ,,
C-H i.p.def. (asym.) 1472 1470-1435     ,,
C-H o.o.p. def. (sym.) 1386 1390-1370     ,,
Aromatic C-H  str. 3079 3090-3030    47
C=C str. 1512 1540-1480     ,,
Pyrimidine C=C str. 1530 1580-1520     ,,
moity C-H str. 3068 3080-3030     ,,
C-H i.p. def. 1100 1125-1090     ,,
Amide -NH str. 3398 3410-3380     46
-NH def. 1607 1635-1595     ,,
Carbonyl            -C=O str. 1706 1700-1725     ,,
 Amide               - C=O str. 1651 1690-1660             ,,
Isopropyl  C-H str. 1375 1385-1365      ,,
Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:



































































    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
   1       1.45                   3H singlet C-CH3(a)       -
   2       1.63                   3H singlet C-CH3(b)       -
   3       3.84                   1H singlet Ar-CH(c)       -
   4       4.85                   1H doublet Ar-CH(d)       -
   5       7.13-7.58           6H multiplet Ar-CH       -
                    (h,h’,j,j’,k,k’)
   6       7.58-7.62           2H dd Ar-CH(i,i’)    J=6.0
   7       8.89                   1H singlet Ar-NH(e)       -
   8       9.05                   1H doublet Ar-NH(g)       -
   9       9.89                   1H singlet Ar-NH(f)       -
Internal Standard : TMS; Solvent : CDCl3 : Instrument : BRUKER

















































































































































SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-FLUOROPHENYL)-
6-ISOPROPYL-4-ARYL-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE- 5-
CARBOXAMIDES
(A) Synthesis of 4-Methyl-N-(4-fluorophenyl)-3-oxopentanamide
A mixture of methyl-4-methyl-3-oxopentanoate (methyl isobutrylacetate) (1.44
gm, 0.01 mol) and 4-fluoroaniline (1.23 gm, 0.01 mol) in toluene containing few drops
of ethylene diamine was refluxed for 12 hr and collect methanol using dean and stark.
The resulting solution was cooled to 00C. Than add dilute HCL solution in toluene layer,
theseperated toluene layer washed with three times water and distilled out under vaccum.
The seperated solid was crystallized from hexane-ethylacetate mixture  Yield 67%, m.
p. 650C, Anal.Calcd. for C12H14FNO2 Calcd: C, 64.56; H, 6.32; N, 6.27%, Found:
C, 64.54; H, 6.29; N, 6.28%.
(B) Synthesis of N-(4-Fluorophenyl)-6-isopropyl-4-aryl-2-thioxo-1,2,3,4-
tetrahydropyrimidine- 5-carboxamide
A mixture of thiourea (0.76 gm, 0.01 mol), p-fluorobenzaldehyde (1.24 gm, 0.01
mol) and 4-methyl-N-(4-fluorohenyl)-3-oxo-pentanamide (2.23 gm, 0.01 mol) in 15 ml
of ethanol containing few drops of concentrated hydrochloric acid was refluxed for 24
hr. The solution was allowed to stand for 12 hr. at room temperature. The resulting solid
mass separated was filtered and, crystallized from dioxane.Yield 52%, m.p.2870C,
Anal.Calcd. for C20H19F2N3OS Calcd: C,62.00; H, 4.94; N, 10.85%, Found:  C, 61.98;
H, 4.93; N, 10.84%.
Similarly, other dihydropyrimidinthiones were prepared. The physical data are
recorded in Table No. 14
(C) Biological screening N-(4-Fluorophenyl)-6-isopropyl-4-aryl-2-thioxo-
1,2,3,4-tetrahydropyrimidine- 5-carboxamides
Antimicrobial testing were carried out as described in Part-I(A) Section-I(D).
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C6H5-
4-NO2-C6H4-
3-NO2-C6H4-
4-CH3-C6H4-
2-Cl-C6H4-
4-Cl-C6H4-
3-Cl-C6H4-
3,4-(OCH3)2-C6H3-
3-O-C6H5-C6H4-
4-OCH3-C6H4-
4-F-C6H4-
3-Br-C6H4-
C6H5-
4-NO2-C6H4-
3-NO2-C6H4-
2-Cl-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
3-Cl-C6H4-
3,4-(OCH3)2-C6H3-
3-O-C6H5-C6H4-
4-OCH3-C6H4-
4-F-C6H4-
3-Br-C6H4-
NH
N
H
RO
NH
CH3
CH3
S
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CH3
NH
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CH3
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